<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Non‐steroidal anti‐inflammatory agents for treating cystoid macular edema following cataract surgery - Wingert, AM - 2022 | Cochrane Library</title> <meta content="Non‐steroidal anti‐inflammatory agents for treating cystoid macular edema following cataract surgery - Wingert, AM - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004239.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Non‐steroidal anti‐inflammatory agents for treating cystoid macular edema following cataract surgery - Wingert, AM - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004239.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004239.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Non‐steroidal anti‐inflammatory agents for treating cystoid macular edema following cataract surgery" name="citation_title"/> <meta content="Andreas M Wingert" name="citation_author"/> <meta content="Haverford College" name="citation_author_institution"/> <meta content="Su-Hsun Liu" name="citation_author"/> <meta content="John C Lin" name="citation_author"/> <meta content="Brown University" name="citation_author_institution"/> <meta content="Jayanth Sridhar" name="citation_author"/> <meta content="Bascom Palmer Eye Institute" name="citation_author_institution"/> <meta content="jsridhar119@gmail.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD004239.pub4" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/12/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004239.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004239.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004239.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; *Cataract [complications]; Diclofenac [therapeutic use]; Ketorolac [therapeutic use]; *Macular Edema [drug therapy, etiology]; Prednisolone [therapeutic use]; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004239.pub4&amp;doi=10.1002/14651858.CD004239.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004239\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004239\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004239.pub4",title:"Non\\u2010steroidal anti\\u2010inflammatory agents for treating cystoid macular edema following cataract surgery",firstPublishedDate:"Dec 15, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004239.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004239.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004239.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004239.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004239.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004239.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004239.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004239.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004239.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004239.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3474 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004239.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-sec-0113"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/appendices#CD004239-sec-0118"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/supinfo/CD004239StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/supinfo/CD004239StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Non‐steroidal anti‐inflammatory agents for treating cystoid macular edema following cataract surgery </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/information#CD004239-cr-0004">Andreas M Wingert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/information#CD004239-cr-0005">Su-Hsun Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/information#CD004239-cr-0006">John C Lin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004239.pub4/information#CD004239-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Jayanth Sridhar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/information/en#CD004239-sec-0130">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 December 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004239.pub4">https://doi.org/10.1002/14651858.CD004239.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004239-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004239-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004239-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004239-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004239-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004239-abs-0005">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004239-abs-0001" lang="en"> <section id="CD004239-sec-0001"> <h3 class="title" id="CD004239-sec-0001">Background</h3> <p>Cataract surgery is the most common ambulatory incisional surgery performed in the USA. Cystoid macular edema (CME), the accumulation of fluid in the central retina due to leakage from dilated capillaries, is the most common cause of vision impairment following cataract surgery. Acute CME, defined as CME of less than four months' duration, often resolves spontaneously. CME that persists for four months or longer is termed chronic CME. Non‐steroidal anti‐inflammatory drugs (NSAIDs) have been used to treat CME. This update adds new evidence and analyses to the previously published review. </p> </section> <section id="CD004239-sec-0002"> <h3 class="title" id="CD004239-sec-0002">Objectives</h3> <p>To examine the effectiveness of NSAIDs in the treatment of CME following cataract surgery. </p> </section> <section id="CD004239-sec-0003"> <h3 class="title" id="CD004239-sec-0003">Search methods</h3> <p>We searched the CENTRAL (2022, Issue 3); Ovid MEDLINE; Embase; PubMed; LILACS; <i>m</i>RCT (discontinued in 2014, last searched August 2011), ClinicalTrials.gov, and WHO ICTRP databases. We did not use any date or language restrictions in the electronic search for trials. We last searched the electronic databases on 20 March 2022.   </p> </section> <section id="CD004239-sec-0004"> <h3 class="title" id="CD004239-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials evaluating the effects of NSAIDs for CME following cataract surgery. </p> </section> <section id="CD004239-sec-0005"> <h3 class="title" id="CD004239-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened all titles and abstracts, reviewed full‐text publications against eligibility criteria, independently extracted data from newly included trials and assessed risk of bias for each included trial. We contacted trial authors for clarification or to request missing information. We provided a narrative synthesis of all included trials and their results. For continuous and dichotomous outcomes, we separately performed pooled analysis and reported mean difference (MD) and risk ratio (RR) as well as the associated 95% confidence interval (CI) whenever feasible. Two review authors independently graded the overall certainty of the evidence for each outcome using the GRADE approach. </p> </section> <section id="CD004239-sec-0006"> <h3 class="title" id="CD004239-sec-0006">Main results</h3> <p>We included nine trials with a total of 390 participants (393 eyes). Study participants' mean age was 72.2 years (interquartile range [IQR] 68.8 to 73.6) and 72% were women (IQR 69% to 74%). Three trials included participants with acute CME, and four included participants with chronic CME; the remaining two trials enrolled both participants with acute and chronic CME or participants with unknown CME duration. We assessed trials as having unclear (33%) or high risk of bias (67%). </p> <p><b>Visual improvement of two or more lines at the end of treatment </b> </p> <p>Data from one trial in participants with acute CME show no treatment effect of topical ketorolac compared to placebo (RR 2.00, 95% CI 0.46 to 8.76; 22 participants). Data from a three‐arm trial in participants with acute CME demonstrate that, when compared with topical prednisolone, topical ketorolac (RR 1.33, 95% CI 0.58 to 3.07; 17 participants) or topical ketorolac and prednisolone combination therapy (RR 1.78, 95% CI 0.86 to 3.69; 17 participants) may have little or no effect on visual improvement. Results of subgroup analysis from two studies in participants with chronic CME suggest that, after treatment for 90 days or longer, NSAIDs may increase participants' likelihood of visual improvement by 1.87 fold (RR 2.87, 95% CI 1.58 to 5.22; I<sup>2</sup> = 33%; 2 trials, 121 participants) relative to placebo. However, there was no evidence of treatment effects in the subgroup with two months of treatment or less (RR 0.72, 95% CI 0.30 to 1.73; P = 0.19, I<sup>2</sup> = 41%; 2 trials, 34 participants). Overall, this evidence is very low certainty.  </p> <p>A single‐study estimate in patients with mixed CME indicates that topical diclofenac may increase the likelihood of visual improvement by 40% when compared to topical ketorolac (RR 1.40, 95% CI 1.02 to 1.94; 68 participants). However, the same trial reported no difference between the groups in mean final visual acuity in Snellen lines (MD 0.40, 95% CI −0.93 to 1.73). A three‐arm trial in patients with mixed CME reporting visual changes in ETDRS letters in comparisons between ketorolac and diclofenac (34 participants) or bromfenac (34 participants) suggests no evidence of effects. Overall, NSAIDs may slightly improve visual acuity in participants with mixed CME but the evidence is very uncertain. </p> <p><b>Persistence of improvement of vision one month after discontinuation of treatment</b> </p> <p>One trial of participants with chronic CME tested oral indomethacin (RR 0.40, 95% CI 0.10 to 1.60; 20 participants) and the other compared topical ketorolac to placebo (RR 4.00, 95% CI 0.51 to 31.1; 26 participants). While there is no evidence of treatment effects, evidence suggests substantial between‐group heterogeneity (P = 0.07, I<sup>2</sup> = 69.9%; very low‐certainty evidence). None of the trials in patients with acute or mixed CME reported this outcome. </p> <p><b>Proportion of participants with improvement in leakage on fundus fluorescein angiography</b> </p> <p>One three‐arm trial in participants with acute CME shows that, when compared with topical prednisolone, there is no treatment benefit of topical ketorolac (RR 1.11, 95% CI 0.45 to 2.75; 17 participants) or topical ketorolac and topical prednisolone combination therapy (RR 1.56, 95% CI 0.72 to 3.38; 17 participants). This evidence is very low certainty. </p> <p>The combined estimate from two trials in participants with chronic CME indicates NSAIDs have little to no effect over placebo on improving leakage (RR 1.93, 95% CI 0.62 to 6.02; 40 participants; very low‐certainty evidence). Neither of the trials in patients with mixed CME reported this outcome. </p> <p><b>Proportion of participants with improved contrast sensitivity</b> </p> <p>Very low‐certainty evidence from one trial in participants with acute CME shows no treatment benefit of ketorolac (RR 1.11, 95% CI 0.45 to 2.75; 17 participants) or ketorolac and prednisolone combination therapy (RR 1.78, 95% CI 0.86 to 3.69; 17 participants) compared with topical prednisolone. None of the trials in patients with chronic or mixed CME reported this outcome. </p> <p><b>Proportion of participants with improved central macular thickness on optical coherence tomography; measures of quality of life</b> </p> <p>No included trial reported these outcomes.</p> <p><b>Adverse effects</b> </p> <p>Most trials observed no differences in ocular adverse events, such as corneal toxicity or elevated intraocular pressure, between comparison groups. </p> </section> <section id="CD004239-sec-0007"> <h3 class="title" id="CD004239-sec-0007">Authors' conclusions</h3> <p>Evidence on effects of NSAIDs in patients with CME is very uncertain and further investigation is warranted. Our findings are limited by small sample sizes, and heterogeneity in interventions, assessments, and reporting of clinically important outcomes.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004239-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004239-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004239-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004239-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004239-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004239-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004239-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004239-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004239-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004239-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004239-abs-0002" lang="en"> <h3>What are the benefits of NSAIDs for treating fluid accumulation in the central retina (macula) after cataract surgery? </h3> <p><b>Key messages</b> </p> <p>• We updated the evidence on the effects of non‐steroidal anti‐inflammatory drugs (NSAIDs, such as ibuprofen) among individuals with acute or chronic fluid accumulation in the central retina (macula) after cataract surgery. </p> <p>• There was only very uncertain evidence that NSAIDs could improve vision or reduce fluid accumulation in the macula. </p> <p>• More research is warranted to provide quality evidence.</p> <p><b>What is cystoid macular edema (CME)?</b> </p> <p>Cataract surgery is the most common outpatient surgery performed in the USA. Sometimes after cataract surgery, inflammation inside the eye leads to leakage of fluid from retinal blood vessels, which results in the accumulation of fluid in cyst‐like spaces and swelling of the central part of the retina (macula). This is called 'cystoid macular edema', or CME, and may cause reduced or distorted vision. CME is one of the most frequent complications following cataract surgery. </p> <p><b>How is CME treated?</b> </p> <p>CME after cataract surgery is often treated with NSAIDs or other medications to reduce inflammation inside the eye. NSAIDs are usually applied directly to the eye (topical) as eyedrops; they may be given alone or with another medication, such as a topical steroid or another NSAID. </p> <p><b>What did we want to find out?</b><br/>We wanted to know whether NSAIDs, given alone or combined with other medications, can help people with CME following cataract surgery to see more clearly. </p> <p><b>What did we do?</b><br/>We searched for studies that randomly assigned adults with CME after cataract surgery to be treated with NSAIDs, alone or with other medications. Studies compared NSAIDs with placebo (a dummy medicine with no active ingredients) or other active treatment (steroid or another NSAID). We compared and summarized the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We included 9 studies that involved a total of 390 people with a mean age of 72 years; 72% were women. Three studies enrolled exclusively people with acute CME (fluid accumulation in the macula of less than 4 months' duration) after cataract surgery, 4 studies enrolled people with chronic CME (fluid presence in the macula which persisted for 4 months or longer) after cataract surgery, and the remaining 2 studies included people with varying durations of post‐surgical fluid accumulation in the macula. </p> <p><b>• People with acute CME:</b> NSAIDs might improve vision or reduce retinal swelling compared to placebo or a topical steroid (3 studies). </p> <p><b>• People with chronic CME:</b> 2 studies that treated people with chronic CME with NSAIDs for two months or less showed no effects on vision improvement. In contrast, the other two studies suggested that NSAIDs might improve vision after 90 to 120 days of treatment. We did not find any evidence about the effects of NSAIDs on other outcomes, such as persistent improvement of vision after treatment stopped or reduced fluid accumulation in the macula. </p> <p><b>• Length of time with CME not known:</b> topical NSAID might have little or no effects on vision compared to a different NSAID. </p> <p>Most of the included studies either did not report data on unwanted effects or did not report differences in unwanted effects between groups receiving different treatments.  </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence was limited because studies did not include many participants, and they used different medications in different amounts for different durations. The studies did not examine all the outcomes of interest. The findings were also limited by the fact that the trials were published from 1977 to 2006, and many advances in cataract surgery techniques have occurred throughout and since that time. </p> <p><b>How up to date is this evidence?</b><br/>The evidence is up to date as of March 2022. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004239-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004239-sec-0113"></div> <h3 class="title" id="CD004239-sec-0114">Implications for practice</h3> <section id="CD004239-sec-0114"> <p>For chronic CME, topical ketorolac tromethamine 0.5% may improve visual acuity with at least three months of treatment but the evidence was very low certainty. Overall, there was no evidence that NSAIDs had clinically meaningful effects on any pre‐specified review outcomes in any type of CME; further investigation is warranted. </p> </section> <h3 class="title" id="CD004239-sec-0115">Implications for research</h3> <section id="CD004239-sec-0115"> <p>Further investigation is needed to better understand the pathophysiology and risk factors of CME; such research would permit identification of those eyes most at risk for CME, and may elucidate strategies to prevent CME. In addition, research is needed to better elucidate the incidence, time course, and factors predictive of spontaneous resolution of acute CME versus those predictive of chronic CME; such research may permit targeted treatment to those individuals likely to need treatment for resolution of CME and optimal visual outcomes. </p> <p>Larger trials with longer follow‐up are needed to assess the efficacy of NSAIDs in treating CME. Studies are also needed to compare the relative efficacy of various available topical NSAIDs for the treatment of acute and chronic CME following cataract surgery, and to determine the optimal duration of treatment. Despite the paucity and low certainty of evidence regarding the effectiveness of NSAIDs on clinically important outcomes of CME treatment, NSAIDs, with or without a topical steroid, remain a first‐line therapy for CME following cataract surgery (<a href="./references#CD004239-bbs2-0051" title="OrskiM , GawęckiM . Current management options in Irvine-Gass syndrome: a systemized review. Journal of Clinical Medicine2021;10(19):4375.">Orski 2021</a>). Research is needed to compare the effectiveness of NSAIDs with alternative treatments such as steroids, anti‐vascular endothelial growth factor (anti‐VEGF) agents, and combination therapies such as an NSAID plus steroids. In addition, there is a need for comparative cost‐effectiveness research to compare the use of NSAIDs in the prevention versus treatment of CME following cataract surgery. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004239-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004239-sec-0008"></div> <div class="table" id="CD004239-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">NSAID versus placebo or active control in acute cystoid macular edema</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Non‐steroidal anti‐inflammatory drug vs placebo or active control for acute cystoid macular edema following cataract surgery</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient population:</b> participants with acute CME (&lt; 4 months) following cataract surgery </p> <p><b>Settings:</b> private clinics or medical centers in the USA </p> <p><b>Intervention:</b> ketorolac, diclofenac </p> <p><b>Comparison:</b> placebo, prednisolone, ketorolac + prednisolone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk*</b> </p> <p><b>Placebo or prednisolone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> <p><b>NSAID ± prednisolone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Visual improvement at end of treatment, as defined by two or more Snellen lines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b><br/>18 per 100  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac</b> </p> <p>36 (8 to 100) </p> <p>per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.00 (0.46 to 8.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RR &gt; 1 is better.</p> <p>Besides <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a> (22 participants) and <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a> (26 participants),  </p> <p><a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a> (34 participants) compared mean final VA between participants receiving ketorolac with those receiving diclofenac (20/50 vs 20/49) and concluded no overall differences </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Prednisolone</b> </p> <p>50 per 100 </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac</b> </p> <p>67 (29 to 100)</p> <p>per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.33</p> <p>(0.58 to 3.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac + prednisolone</b> </p> <p>89 (43 to 100)</p> <p>per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.78</p> <p>(0.86 to 3.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of visual improvement one month after discontinuation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Improvement in leakage on FFA</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Prednisolone</b> </p> <p>50 per 100 </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac</b> </p> <p>56 (23 to 100) per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11</p> <p>(0.45 to 2.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR &gt; 1 is better.</p> <p>Data from the same 3‐arm trial (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac + prednisolone</b> </p> <p>78 (36 to 100) per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.56</p> <p>(0.72 to 3.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in central macular thickness on OCT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Improved contrast sensitivity</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Prednisolone</b> </p> <p>50 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac</b> </p> <p>56 (23 to 100) per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11</p> <p>(0.45 to 2.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR &gt; 1 is better</p> <p>Data from the same 3‐arm trial (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac + prednisolone</b> </p> <p>89 (43 to 100) per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.78</p> <p>(0.86 to 3.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and the associated 95% CI). </p> <p> </p> <p><b>CI:</b> confidence interval; <b>CME:</b> cystoid macular edema; <b>FFA:</b> fundus fluorescein angiography (angiogram); <b>NSAID:</b> non‐steroidal anti‐inflammatory drug; <b>OCT:</b> optical coherence tomography; <b>QoL:</b> quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias (‐1), imprecision (‐1) and heterogeneity (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004239-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NSAID versus placebo in chronic cystoid macular edema</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Non‐steroidal anti‐inflammatory drug vs active control for chronic cystoid macular edema following cataract surgery</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient population:</b> participants with chronic CME (≥ 4 months) following cataract surgery </p> <p><b>Settings:</b> medical centers in the USA </p> <p><b>Intervention:</b> topical ketorolac, topical fenoprofen, oral indomethacin </p> <p><b>Comparison:</b> placebo (vehicle or saline) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk*</b> </p> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> <p><b>NSAID</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Visual improvement at end of treatment, as defined by two or more Snellen lines</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Treatment duration ≤ 2 months</b> </p> <p>44 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 (13 to 76) </p> <p>per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72</p> <p>(0.30 to 1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR &gt; 1 is better.</p> <p>When excluding <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>, which examined oral NSAID, there was no evidence of subgroup differences and the combined RR was 2.33 (95% CI 1.17 to 4.66; 3 RCTs, 135 participants), favoring topical NSAIDs over placebo in visual improvement after at least 90 days of treatment. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Treatment duration 90‐120 days</b> </p> <p>18 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 (28 to 94) </p> <p>per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.87</p> <p>(1.58 to 5.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(2 RCTs)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of visual improvement one month after discontinuation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 (11 to 80)</p> <p>per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17</p> <p>(0.44 to 3.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in leakage on FFA</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 (9 to 84)</p> <p>per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.93</p> <p>(0.62 to 6.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 is better.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in central macular thickness on OCT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not measured by any included trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improved contrast sensitivity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not measured by any included trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not measured by any included trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and the associated 95% CI). </p> <p> </p> <p><b>CI:</b> confidence interval; <b>CME:</b> cystoid macular edema; <b>FFA:</b> fundus fluorescein angiography (angiogram); <b>NSAID:</b> non‐steroidal anti‐inflammatory drug; <b>OCT:</b> optical coherence tomography; <b>QoL:</b> quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias (‐1), imprecision (‐1) and heterogeneity (‐1).<br/><sup>b</sup>Downgraded for risk of bias (‐1) and extreme imprecision (‐2). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004239-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NSAID versus active control in mixed cystoid macular edema</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Non‐steroidal anti‐inflammatory drug vs active control for cystoid macular edema following cataract surgery</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient population:</b> participants with acute or chronic CME following cataract surgery </p> <p><b>Settings:</b> private clinics in the USA or medical centers in Canada </p> <p><b>Intervention:</b> bromfenac, diclofenac ± prednisolone, ketorolac ± prednisolone </p> <p><b>Comparison:</b> ketorolac ± prednisolone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* </b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk*</b> </p> <p><b>Active control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> <p><b>NSAID</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Visual improvement at end of treatment, as defined by two or more Snellen lines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Diclofenac + prednisolone</b> </p> <p>59 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac + prednisolone</b> </p> <p>83 (60 to 100)</p> <p>per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> </p> <p>(1.02 to 1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 is better.</p> <p><a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> also reported this outcome in Snellen lines (MD 0.40, 95% CI −0.93 to 1.73; 68 participants)  </p> <p><a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a> reported in ETDRS letters (MD 0.90, 95% CI −4.31 to 6.11; 34 participants) considering data from the diclofenac group or  </p> <p>(MD 1.20, 95% CI −4.58 to 6.98; 34 participants) considering </p> <p>data from the bromfenac group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of visual improvement one month after discontinuation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in leakage on FFA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in central macular thickness on OCT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improved contrast sensitivity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and the associated 95% CI). </p> <p> </p> <p><b>CI:</b> confidence interval; <b>CME:</b> cystoid macular edema; <b>ETDRS:</b> Early Treatment Diabetic Retinopathy Study; <b>FFA:</b> fundus fluorescein angiography (angiogram); <b>NSAID:</b> non‐steroidal anti‐inflammatory drug; <b>OCT:</b> optical coherence tomography; <b>QoL:</b> quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias (‐1), imprecision (‐1) and inconsistency (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004239-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004239-sec-0009"></div> <p>Cystoid macular edema (CME) is the presence of excess fluid in the extracellular space of the neurosensory retina presenting clinically with cyst‐like spaces and abnormal thickening of the central part of the retina (the macula). Cystoid macular edema following cataract surgery was first described by Irvine in 1953 (<a href="./references#CD004239-bbs2-0044" title="IrvineSR . A newly defined vitreous syndrome following cataract surgery. American Journal of Ophthalmology1953;36(5):599-619.">Irvine 1953</a>), and Gass and Norton published the first detailed microscopic and fluorescein angiographic description of this condition in 1966 (<a href="./references#CD004239-bbs2-0037" title="GassJD , NortonEW . Cystoid macular edema and papilledema following cataract extraction: a fluorescein fundoscopic and angiographic study. Archives of Ophthalmology1966;76(5):646-61.">Gass 1966</a>); the entity later became known as Irvine‐Gass syndrome or pseudophakic CME. Cataract surgery is the most common ambulatory incisional surgery performed in the USA (<a href="./references#CD004239-bbs2-0058" title="SteinerCA , KaracaZ , MooreBJ , ImshaugMC , PickensG . Surgeries in hospital-based ambulatory surgery and hospital inpatient settings, 2014. 2017 May [Updated 2020 Jul 20]. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb. Statistical Brief #223. Available from www.ncbi.nlm.nih.gov/books/NBK442035/ (accessed after July 2020).">Steiner 2014</a>), with CME being one of its most frequent postoperative complications. </p> <section id="CD004239-sec-0010"> <h3 class="title" id="CD004239-sec-0010">Description of the condition</h3> <p>Pseudophakic CME impairing patients’ vision has been reported to occur in 1% to 2% of patients, with a peak incidence occurring six weeks postoperatively, but subclinical CME may be observed on fluorescein angiography in about 30% of patients, and on optical coherence tomography in up to 40% of patients (<a href="./references#CD004239-bbs2-0041" title="HendersonBA , KimJY , AmentCS , Ferrufino-PonceZK , GrabowskaA , CremersSL . Clinical pseudophakic cystoid macular edema: risk factors for development and duration after treatment. Journal of Cataract and Refractive Surgery2007;33(9):1550-8.">Henderson 2007</a>; <a href="./references#CD004239-bbs2-0052" title="PerenteI , UtineCA , OzturkerC , CakirM , KayaV , ErenH , et al. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Current Eye Research2007;32(3):241-7.">Perente 2007</a>; <a href="./references#CD004239-bbs2-0057" title="ShelstaHN , JampolLM . Pharmacologic therapy of pseudophakic cystoid macular edema: 2010 update. Retina2011;31(1):4-12.">Shelsta 2010</a>). Despite the many advances in cataract surgery techniques, clinically significant CME following modern cataract surgery has been reported to occur in about 2% of cases (<a href="./references#CD004239-bbs2-0045" title="KesselL , TendalB , JørgensenKJ , ErngaardD , FlesnerP , AndresenJL , et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology2014;121(10):1915-24.">Kessel 2014</a>; <a href="./references#CD004239-bbs2-0047" title="MalwankarJ , SonHS , ChangDF , DunC , WoretaF , PrescottC , et al. Trends, factors, and outcomes associated with immediate sequential bilateral cataract surgery among Medicare beneficiaries. Ophthalmology2022;129(5):478-87.">Malwankar 2022</a>; <a href="./references#CD004239-bbs2-0059" title="TaipaleC , HolmströmEJ , IlveskoskiL , TuuminenR . Incidence of pseudophakic cystoid macular edema in eyes with and without pupil expansion device. Acta Ophthalmologica2019;97(7):688-94.">Taipale 2019</a>). </p> <section id="CD004239-sec-0011"> <h4 class="title">Presentation and diagnosis</h4> <p>Pseudophakic CME may be asymptomatic or present with decreased or distorted vision, or both, with a peak incidence six weeks after cataract surgery. Slit‐lamp biomicroscopy may demonstrate retinal thickening; a blunted, or loss of, foveal depression; a yellowish appearance of the central macula; and a honeycomb appearance at the macula. Clinical findings may be best observed using a fundus contact lens, and red‐free light may facilitate detection of cystic changes. Fluorescein angiography may demonstrate perifoveal retinal telangiectasis, dilated capillaries, and perifoveal leakage in a 'petaloid’ pattern. Optic nerve staining may also be observed and helps to distinguish pseudophakic CME from other causes of CME. On optical coherence tomography, CME is characterized by a loss of the foveal depression, retinal thickening, intraretinal cystic hyporeflective lesions and, in some cases, hyporeflectivity under the central macula, indicating the presence of subretinal fluid. </p> </section> </section> <section id="CD004239-sec-0012"> <h3 class="title" id="CD004239-sec-0012">Description of the intervention</h3> <p>Although the pathogenesis of pseudophakic CME remains incompletely understood, it is believed that inflammation leading to a breakdown of the blood‐retinal barrier plays a major role. It has been hypothesized that surgical manipulation causes significant release, by the anterior uveal tissue, of prostaglandins and other inflammatory mediators; the latter increase permeability of the perifoveal capillaries, leading to accumulation of fluid and cystic changes in the outer plexiform and inner nuclear layers of the retina (<a href="./references#CD004239-bbs2-0050" title="MiyakeK , IbarakiN . Prostaglandins and cystoid macular edema. Survey of Ophthalmology2002;47 Suppl 1:S203-18.">Miyake 2002</a>). Corticosteroids and non‐steroidal anti‐inflammatory drugs (NSAIDs) have been used both pre‐ and postoperatively to try to prevent and treat pseudophakic CME (<a href="./references#CD004239-bbs2-0031" title="BrandsdorferA , PatelSH , ChuckRS . The role of perioperative nonsteroidal anti-inflammatory drugs use in cataract surgery. Current Opinion in Ophthalmology2019;30(1):44-9.">Brandsdorfer 2019</a>; <a href="./references#CD004239-bbs2-0039" title="GrzybowskiA , SikorskiBL , AscasoFJ , HuervaV . Pseudophakic cystoid macular edema: update 2016. Clinical Interventions in Aging2016;9(11):1221-9.">Grzybowski 2016</a>; <a href="./references#CD004239-bbs2-0051" title="OrskiM , GawęckiM . Current management options in Irvine-Gass syndrome: a systemized review. Journal of Clinical Medicine2021;10(19):4375.">Orski 2021</a>). </p> </section> <section id="CD004239-sec-0013"> <h3 class="title" id="CD004239-sec-0013">How the intervention might work</h3> <p>It is hypothesized that inflammation plays a major role in the pathogenesis of CME. Since NSAIDs inhibit cyclooxygenase, a rate‐limiting enzyme in the production of prostaglandins, NSAIDs may be effective in treating CME by reducing the production of inflammatory factors.  </p> </section> <section id="CD004239-sec-0014"> <h3 class="title" id="CD004239-sec-0014">Why it is important to do this review</h3> <p>This is an update of a review last published in 2012, which examined the effects of topical NSAIDs on acute CME (3 trials) and chronic CME (4 trials), and concluded that the effects of NSAIDs in both acute and chronic CME remained unclear (<a href="./references#CD004239-bbs2-0064" title="SivaprasadS , BunceC , Crosby-NwaobiR . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub3]">Sivaprasad 2012</a>). Therefore, we attempted to update the evidence base by including newly available trials evaluating treatment effects of topical NSAIDs on either acute or chronic CME, and by including additional analyses. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004239-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004239-sec-0015"></div> <p>To examine the effectiveness of NSAIDs in the treatment of CME following cataract surgery. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004239-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004239-sec-0016"></div> <section id="CD004239-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004239-sec-0018"> <h4 class="title">Types of studies</h4> <p>This review included randomized controlled trials (RCTs).</p> </section> <section id="CD004239-sec-0019"> <h4 class="title">Types of participants</h4> <p>Participants in the trials were adults who developed CME following cataract surgery in an eye with no history of ocular inflammatory disease, trauma or previous intraocular surgery. Surgery and the postoperative course of cataract are different in children and adults, so we excluded children from the review. We classified CME as either acute, defined as edema of less than four months' duration, or chronic, defined by CME that had persisted for four months or longer. In the current update, we also considered inclusion of trials that did not specify types of CME in their inclusion criteria (see <a href="#CD004239-sec-0134">Differences between protocol and review</a>). </p> </section> <section id="CD004239-sec-0020"> <h4 class="title">Types of interventions</h4> <p>We included trials that compared NSAIDs in any form or dosage to placebo, no treatment or another treatment modality with the aim of treating CME following cataract surgery. There was no minimum or maximum limit on the duration of treatment. To be consistent with the previous reviews (<a href="./references#CD004239-bbs2-0062" title="SivaprasadS , BunceC , JyothiS . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub2]">Sivaprasad 2004</a>; <a href="./references#CD004239-bbs2-0063" title="SivaprasadS , BunceC , JyothiS . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub2]">Sivaprasad 2009</a>; <a href="./references#CD004239-bbs2-0064" title="SivaprasadS , BunceC , Crosby-NwaobiR . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub3]">Sivaprasad 2012</a>), we also considered trials that compared different NSAIDs as eligible. </p> </section> <section id="CD004239-sec-0021"> <h4 class="title">Types of outcome measures</h4> <section id="CD004239-sec-0022"> <h5 class="title">Primary outcomes</h5> <section id="CD004239-sec-0023"> <h6 class="title">Critical outcomes</h6> <p> <ul id="CD004239-list-0001"> <li> <p>Improvement of visual acuity, defined by two or more lines in Snellen visual acuity or equivalent, at the end of treatment </p> </li> <li> <p>Persistence of visual improvement one month after discontinuation of treatment</p> </li> </ul> </p> </section> </section> <section id="CD004239-sec-0024"> <h5 class="title">Secondary outcomes</h5> <section id="CD004239-sec-0025"> <h6 class="title">Important outcomes</h6> <p> <ul id="CD004239-list-0002"> <li> <p>Improvement in CME, quantified by proportion of participants with:</p> <ul id="CD004239-list-0003"> <li> <p>improvement in leakage on fundus fluorescein angiography (FFA) as defined by the original study;  </p> </li> <li> <p>improvement in central macular thickness on optical coherence tomography (OCT) as defined by the original study; or </p> </li> <li> <p>improvement in contrast sensitivity.</p> </li> </ul> </li> <li> <p>Change in quality of life as measured by validated questionnaires such as the National Eye Institute Visual Function Questionnaire (NEI‐VFQ 25; <a href="./references#CD004239-bbs2-0048" title="MangioneCM , LeePP , GutierrezPR , SpritzerK , BerryS , HaysRD , et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Archives of Ophthalmology2001;119(7):1050-8.">Mangione 2001</a>) or the 36‐Item Short Form Health Survey (SF‐36; <a href="./references#CD004239-bbs2-0040" title="HaysRD , MoralesLS . The RAND-36 measure of health-related quality of life. Annals of Medicine2001;33:350-7.">Hays 2001</a>). </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD004239-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004239-sec-0027"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist searched the following electronic databases for randomized controlled trials and controlled clinical trials. There were no language or publication year restrictions. The electronic databases were last searched on 20 March 2022. </p> <p> <ul id="CD004239-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2022, Issue 3) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched 20 March 2022) (<a href="./appendices#CD004239-sec-0119">Appendix 1</a>). </p> </li> <li> <p>MEDLINE Ovid (1946 to 20 March 2022) (<a href="./appendices#CD004239-sec-0120">Appendix 2</a>). </p> </li> <li> <p>Embase.com (1947 to 20 March 2022) (<a href="./appendices#CD004239-sec-0121">Appendix 3</a>). </p> </li> <li> <p>PubMed (1946 to 20 March 2022) (<a href="./appendices#CD004239-sec-0122">Appendix 4</a>). </p> </li> <li> <p>Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to 20 March 2022) (<a href="./appendices#CD004239-sec-0123">Appendix 5</a>). </p> </li> <li> <p><i>meta</i> Register of Controlled Trials (<i>m</i>RCT) (www.controlled‐trials.com; discontinued in 2014; last searched August 2011) (<a href="./appendices#CD004239-sec-0124">Appendix 6</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://nam02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;data=05%7C01%7Clrosman1%40jhmi.edu%7C209457ab755044d3287b08da8042a2ec%7C9fa4f438b1e6473b803f86f8aedf0dec%7C0%7C0%7C637963320946951155%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=cFH2QaC9tDaXfpwvmwgqQ14PkeQNtfxS5KTMi5sY%2F6I%3D&amp;reserved=0" target="_blank">www.clinicaltrials.gov</a>; searched 20 March 2022) (<a href="./appendices#CD004239-sec-0125">Appendix 7</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="https://nam02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.who.int%2Fictrp&amp;data=05%7C01%7Clrosman1%40jhmi.edu%7C209457ab755044d3287b08da8042a2ec%7C9fa4f438b1e6473b803f86f8aedf0dec%7C0%7C0%7C637963320946951155%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=MarRZTXzSTy8YaoblSbS3%2FgZ80BjshYAmk565kZBvls%3D&amp;reserved=0" target="_blank">www.who.int/ictrp</a>; searched 20 March 2022) (<a href="./appendices#CD004239-sec-0126">Appendix 8</a>). </p> </li> </ul> </p> </section> <section id="CD004239-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We handsearched reference lists of all identified trials and previous reviews for additional trials but did not identify eligible studies. We did not handsearch conference abstracts as they are already included in CENTRAL.  </p> </section> </section> <section id="CD004239-sec-0029"> <h3 class="title" id="CD004239-sec-0029">Data collection and analysis</h3> <section id="CD004239-sec-0030"> <h4 class="title">Selection of studies</h4> <p>The Information Specialist updated the search strategies and performed the searches. We imported separate search results to the web‐based review management software, <a href="./references#CD004239-bbs2-0032" title="Covidence. Version accessed 18 April 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>, to automatically identify and remove duplicates. Two review authors independently screened the titles and abstracts and classified each record as 'relevant (yes)', 'maybe relevant', or 'not relevant (no)' according to the eligibility criteria. We then retrieved full‐text articles that were classified as 'relevant' or 'maybe relevant' for additional review for inclusion. Two review authors independently assessed the full‐text articles and resolved any disagreements by discussion. </p> <p>We also contacted trial authors to request clarification about trial design and the availability of full‐text publications besides the conference abstracts that were available to the review authors. If the trial authors did not respond within two weeks, we used the information available to determine eligibility whenever feasible. Specifically, we classified trials as 'awaiting classification' if they were completed but no trial results were publicly available on the trial registry website or in any indexed databases.  </p> </section> <section id="CD004239-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data in <a href="./references#CD004239-bbs2-0032" title="Covidence. Version accessed 18 April 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a> using data abstraction forms developed by Cochrane Eyes and Vision. We extracted information regarding the trial setting; countries where participant recruitment and intervention took place; sample size; trial duration and treatment duration; trial design elements (unit of randomization, unit of analysis); method of analysis (intent‐to‐treat or complete case analysis); sources of funding and potential conflicts of interests; characteristics of participants; intervention medications and dosage; and study outcomes (domain, specific measurement and metric, method of aggregation, and time points of reporting). Two review authors compared the extracted data, resolving discrepancies by discussion. One review author entered data into <a href="./references#CD004239-bbs2-0053" title="Review Manager Web (RevMan Web). Version 4.13.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a> and a second review author verified the data entered. </p> </section> <section id="CD004239-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the quality of each trial identified for this update and we achieved consensus via discussion. We applied risk of bias assessment following the guidance in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004239-bbs2-0043" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). Specific domains for consideration included the following. </p> <p> <ul id="CD004239-list-0005"> <li> <p>Selection bias: were the randomization procedure and the allocation concealment adequate?</p> </li> <li> <p>Performance bias: were the participants and people administering the treatment masked to the intervention? </p> </li> <li> <p>Attrition bias:</p> <ul id="CD004239-list-0006"> <li> <p>were withdrawals and dropouts completely described?</p> </li> <li> <p>was the analysis by intent‐to‐treat or 'available case' analysis?</p> </li> </ul> </li> <li> <p>Detection bias: were outcome assessors masked to the intervention?</p> </li> <li> <p>Reporting bias: was there selective outcome reporting?</p> </li> </ul> </p> <p>We graded trials as having low risk, high risk or, when the information reported was insufficient to make an assessment, unclear risk of bias. We documented supporting statements for our consensus assessments and presented these overall assessment results in a risk of bias summary figure (<a href="./references#CD004239-bbs2-0043" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). In the current update, we did not exclude trials based on the assessed levels of risk of bias.   </p> </section> <section id="CD004239-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We compared mean differences (MD) for continuous outcomes, such as mean improvement in visual acuity at the end of treatment in lines of Snellen acuity or Early Treatment Diabetic Retinopathy Study (ETDRS) letters. We estimated risk ratios (RR) for comparing dichotomous outcomes, such as proportions of participants with improvement in leakage on FFA or improved contrast sensitivity. We also reported 95% confidence intervals (CI) to express the uncertainty surrounding the point estimates. </p> </section> <section id="CD004239-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>All included trials enrolled participants with only one affected eye, except  for <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>, in which the investigators recruited three participants whose eyes were both treated with the same intervention. All trials reported outcomes at the individual, not the eye, level, including one cross‐over trial (<a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>).  </p> </section> <section id="CD004239-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute any missing data. When the quality or specific metric of the available data prevented any statistical pooling, we excluded the trial from quantitative analyses and reported the data in a narrative manner when appropriate. </p> </section> <section id="CD004239-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined the overall characteristics of the included trials, in particular the types of participants, types of interventions, and study design, to assess the extent to which the studies were sufficiently similar to permit a meaningful meta‐analysis of review outcomes. We considered the size and direction of intervention effects, and took into account the amount of heterogeneity as quantified by the I² statistic (<a href="./references#CD004239-bbs2-0042" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58.">Higgins 2002</a>). As suggested in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004239-bbs2-0034" title="DeeksJJ , HigginsJP , Altman DG editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>), we used the following thresholds to interpret I² values: </p> <p> <ul id="CD004239-list-0007"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD004239-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not assess small‐study effects via funnel plots, which would also signal for potential publication bias, given that fewer than 10 trials contributed data to any meta‐analysis. We assessed selective outcome reporting as part of the risk of bias assessment. </p> </section> <section id="CD004239-sec-0038"> <h4 class="title">Data synthesis</h4> <p>We performed pooled analysis following the guidance in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for data synthesis and analysis (<a href="./references#CD004239-bbs2-0049" title="McKenzieJE , BrennanSE , RyanRE , ThomsonHJ , JohnstonRV . Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">McKenzie 2022</a>). We applied the fixed‐effect model to synthesize data from fewer than three trials reporting the same outcome data. Additionally, we provided a narrative synthesis of all included trials and their results.  </p> <p>We compared NSAIDs with placebo or another active treatment (alone or in combination) and reported treatment effects in RR and the associated 95% CI. In some comparisons, we switched the intervention and comparator groups in the forest plot to present comparison results versus the same comparator (ketorolac 0.5%). </p> </section> <section id="CD004239-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Previous reviews did not plan for any subgroup analysis. We performed post‐hoc subgroup analysis to explore potential sources of heterogeneity, such as treatment duration. </p> </section> <section id="CD004239-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>Previous reviews did not specify any sensitivity analysis. We did not perform any sensitivity analysis either because of the small numbers of trials reporting on the same review outcomes in the pooled analysis. </p> </section> <section id="CD004239-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>For the current update, we prepared summary of findings tables presenting relative or absolute risks (<a href="./references#CD004239-bbs2-0055" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022a</a>). Two review authors independently graded the overall certainty of the evidence for each outcome using the GRADE approach (<a href="./references#CD004239-bbs2-0054" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). </p> <p> <ul id="CD004239-list-0008"> <li> <p>Proportion of participants with improvement of two or more lines in Snellen visual acuity or equivalent at end of treatment </p> </li> <li> <p>Proportion of participants with persistence of vision improvement one month after discontinuation of treatment </p> </li> <li> <p>Proportion of participants with improvement in leakage on FFA</p> </li> <li> <p>Proportion of participants with improvement in central macular thickness on OCT</p> </li> <li> <p>Proportion of participants with improvement in contrast sensitivity</p> </li> <li> <p>Change in quality of life</p> </li> </ul> </p> <p>We graded the certainty of the evidence as 'high,' 'moderate,' 'low,' or 'very low' according to </p> <p> <ul id="CD004239-list-0009"> <li> <p>risk of bias among included trials;</p> </li> <li> <p>indirectness of evidence;</p> </li> <li> <p>unexplained heterogeneity or inconsistency of results;</p> </li> <li> <p>low precision of results; and</p> </li> <li> <p>risk of publication bias (<a href="./references#CD004239-bbs2-0054" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). </p> </li> </ul> </p> <p>We downgraded certainty of the evidence by two levels when contextual considerations suggested extreme imprecision according to the recently published guidance by Schünemann and others (<a href="./references#CD004239-bbs2-0056" title="SchünemannHJ , NeumannI , HultcrantzM , Brignardello-PetersenR , ZengL, MuradMH , et al, for the GRADE Working Group. GRADE Guidance article 35: Update on rating imprecision for assessing contextualized certainty of evidence and making decisions. Journal of Clinical Epidemiology (in press). [DOI: doi.org/10.1016/j.jclinepi.2022.07.015]">Schünemann 2022b</a>). </p> <p>We resolved discrepancies between the two review authors by discussion.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004239-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004239-sec-0042"></div> <section id="CD004239-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD004239-sec-0044"> <h4 class="title">Results of the search</h4> <p>In the first version of the review (<a href="./references#CD004239-bbs2-0062" title="SivaprasadS , BunceC , JyothiS . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub2]">Sivaprasad 2004</a>), review authors screened 382 records and included seven eligible trials involving 266 participants (<a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>; <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>; <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>). Additional updated searches in 2006, 2008, and 2011 resulted in 138, 56, and 77 records, but the review authors did not identify any new eligible trials for the published updates (<a href="./references#CD004239-bbs2-0063" title="SivaprasadS , BunceC , JyothiS . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub2]">Sivaprasad 2009</a>; <a href="./references#CD004239-bbs2-0064" title="SivaprasadS , BunceC , Crosby-NwaobiR . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub3]">Sivaprasad 2012</a>). </p> <p>From the updated searches performed in March 2022, we screened 1560 records and excluded 1547 titles and abstracts. We assessed 13 full‐text articles for eligibility. From these, we found three trials that were already included in the previous review (<a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>), and we excluded five trials with reasons documented for exclusion (<a href="./references#CD004239-bbs2-0010" title="AaronsonA , AchironA , TuuminenR . Clinical course of pseudophakic cystoid macular edema treated with nepafenac. Journal of Clinical Medicine2020;9(9):3034. ">Aaronson 2020</a>; <a href="./references#CD004239-bbs2-0014" title="GinsburgAP , CheethamJK , DeGryseRE , AbelsonM . The effects of flurbiprofen and indomethacin on acute cystoid macular edema: functional vision and contrast sensitivity. Investigative Ophthalmology &amp; Visual Science1994;35:Abstract number 1153. ">Ginsburg 1994</a>; <a href="./references#CD004239-bbs2-0021" title="NCT00438243. Pilot study of the effect of topical bromfenac ophthalmic solution 0.09%in patients with acute post-operative cystoid macular edema. ClinicalTrials.gov/show/NCT00438243 (first received 22 February 2007). ">NCT00438243</a>; <a href="./references#CD004239-bbs2-0022" title="NCT01769352. Treatment of post-surgical cystoid macular edema with topical steroids trial (TEMPEST-1). ClinicalTrials.gov/show/NCT01769352 (first received 16 January 2013). ">NCT01769352</a>; <a href="./references#CD004239-bbs2-0027" title="WolfensbergerTJ , HerbortCP . Treatment of cystoid macular edema with non-steroidal anti-inflammatory drugs and corticosteroids. Documenta Ophthalmologica. Advances in Ophthalmology1999;97(3-4):381-6. ">Wolfensberger 1999</a>). </p> <p>In total, we included two new trials for the current update (<a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>; <a href="#CD004239-fig-0001">Figure 1</a>). We also classified two trials as 'awaiting classification' (<a href="./references#CD004239-bbs2-0028" title="NCT00595543. Treatment of acute pseudophakic cystoid macular edema: bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5%. Clinicaltrials.gov/show/NCT00595543 (first received 16 January 2008). ">NCT00595543</a>; <a href="./references#CD004239-bbs2-0029" title="YükselB , UzunelUD , KerciSG , SağbanL , KüsbeciT , ÖrselT . Comparison of subtenon triamcinolone acetonide injection with topical nepafenac for the treatment of pseudophakic cystoid macular edema. Ocular Immunology and Inflammation2017;25(4):513‐19. ">Yüksel 2017</a>) because of unavailability of trial results or unclear information about study design despite our attempts to contact trial authors. </p> <div class="figure" id="CD004239-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD004239-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD004239-sec-0045"> <h4 class="title">Included studies</h4> <p>In total, we included nine trials (390 participants, 393 eyes) in this review for qualitative synthesis and six in meta‐analyses that each included two to four trials (<a href="#CD004239-fig-0001">Figure 1</a>). </p> <section id="CD004239-sec-0046"> <h5 class="title">Types of studies and setting</h5> <p>All trials included were of parallel‐group design, except for <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>, which randomized the study participants initially and then again at the end of the first 30‐day treatment period. Despite the reported two‐week washout period, the authors of <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a> did not provide separate outcome data for the second treatment period; we decided to extract and use only outcome data reported at the end of the first 30‐day period.  </p> <p>Seven of the trials were two‐arm trials. The remaining two trials were three‐arm trials, which compared the effects of a topical NSAID with two other active treatments (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>). All of the included trials were conducted in the USA. Two trials were conducted in a single medical center (<a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>; <a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>) and one in a private clinic (<a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>); investigators of three other trials reported multi‐site involvement (<a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>). The remaining three trials did not report trial setting (<a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>; <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>). </p> </section> <section id="CD004239-sec-0047"> <h5 class="title">Types of participants</h5> <p>According to the post‐surgical intervals that study participants had from the latest cataract surgery or the duration with which the study participants had been diagnosed with CME before study enrollment, study participants of these nine trials could be classified into those with acute CME, defined as CME of less than four months' duration (<a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>), those with chronic CME, defined as CME which persisted for four months or longer (<a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>; <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>), or those with unspecified CME type (<a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>). Only a few trials provided information about the CME duration when recruiting participants at baseline, which ranged from 4.1 weeks  to 7 weeks for participants with acute CME (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>), and 6 to 24 months for those with chronic CME (<a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>). On average, each trial enrolled a median number of 30 participants (interquartile range [IQR] 22 to 52) or 30 eyes (IQR 23 to 52). Authors of four trials did not report sex distributions (<a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>; <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>) or age compositions (<a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>) of their study participants. Based on other trials that reported age data, the average age of the study participants was 72.2 years (IQR 68.8 to 73.6); 72% were women (IQR 69% to 74%). </p> </section> <section id="CD004239-sec-0048"> <h5 class="title">Types of interventions</h5> <p>We included trials in which NSAIDs in any form or dosage were compared to placebo, no treatment or another therapeutic modality with the aim of treating CME after cataract surgery (previous reviews also included comparisons of different types of NSAIDs [<a href="./references#CD004239-bbs2-0062" title="SivaprasadS , BunceC , JyothiS . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub2]">Sivaprasad 2004</a>; <a href="./references#CD004239-bbs2-0063" title="SivaprasadS , BunceC , JyothiS . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub2]">Sivaprasad 2009</a>; <a href="./references#CD004239-bbs2-0064" title="SivaprasadS , BunceC , Crosby-NwaobiR . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub3]">Sivaprasad 2012</a>]). We did not specify a minimum or maximum duration of treatment.   </p> <p>In the three trials that enrolled patients with acute CME:</p> <p> <ul id="CD004239-list-0010"> <li> <p><a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a> compared the effect of topical ketorolac tromethamine 0.5% with placebo; </p> </li> <li> <p><a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a> compared topical ketorolac tromethamine 0.5% with topical prednisolone acetate 1% as well as with a combination of topical ketorolac tromethamine 0.5% and topical prednisolone acetate 1%; and </p> </li> <li> <p><a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a> compared topical ketorolac tromethamine 0.5% with topical diclofenac sodium 0.1%.   </p> </li> </ul> </p> <p>In the four trials that enrolled patients with chronic CME:</p> <p> <ul id="CD004239-list-0011"> <li> <p><a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a> compared the effect of oral indomethacin with placebo;  </p> </li> <li> <p><a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a> compared topical fenoprofen 1% with placebo; and </p> </li> <li> <p><a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a> and <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a> compared topical ketorolac tromethamine 0.5% with placebo.  </p> </li> </ul> </p> <p>Two trials included participants with CME of unclear duration (<a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>, <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>), and compared NSAID with one or more active treatment:   </p> <p> <ul id="CD004239-list-0012"> <li> <p><a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> reported comparison results of topical ketorolac tromethamine 0.5% versus topical diclofenac sodium 1%; participants in both groups were also treated with topical prednisolone acetate 1%; </p> </li> <li> <p><a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>, a three‐arm trial, compared the effect of topical bromfenac 0.09% with topical diclofenac sodium 0.1% and with topical ketorolac tromethamine 0.5%. </p> </li> </ul> </p> <p>Across these trials, topical ketorolac tromethamine 0.5% was the most frequently used interventional NSAID (<a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>), followed by topical diclofenac sodium 1% (<a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>), topical bromfenac 0.09% (<a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>), topical fenoprofen sodium 1% (<a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>), and oral indomethacin (<a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>). Besides placebo (or vehicle), active treatments under comparison included another NSAID (<a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>; <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>), and topical prednisolone acetate 1% alone (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>) or in combination with another NSAID (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>).  </p> </section> <section id="CD004239-sec-0049"> <h5 class="title">Types of outcomes</h5> <section id="CD004239-sec-0050"> <h6 class="title">Critical outcomes</h6> <section id="CD004239-sec-0051"> <p><b>Improvement of two or more lines in Snellen visual acuity or equivalent at end of treatment</b></p> <p>Six trials reported an improvement in Snellen visual acuity of two or more lines at the end of treatment (<a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>). <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a> and <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> also reported mean final visual acuity in Snellen lines, whereas <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a> reported visual acuity in ETDRS letters. </p> </section> <section id="CD004239-sec-0052"> <p><b>Persistence of improvement of vision one month after discontinuation of treatment</b></p> <p>Three trials reported persistent visual improvement at one month following cessation of treatment (<a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>).    </p> </section> </section> <section id="CD004239-sec-0053"> <h6 class="title">Important outcomes</h6> <section id="CD004239-sec-0054"> <p><b>Proportion of participants with improvement in leakage on FFA</b></p> <p>Six trials performed FFA as a diagnostic or monitoring tool (<a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>; <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>; <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>), although not all participants received repeat FFA at follow‐up in <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>. Only three trials reported decreased leakage on FFA as an outcome measure (<a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>; <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>).  </p> </section> <section id="CD004239-sec-0055"> <p><b>Proportion of participants with improvement in central macular thickness on OCT</b></p> <p>None of the included trials measured this outcome.</p> </section> <section id="CD004239-sec-0056"> <p><b>Proportion of participants with improved contrast sensitivity</b></p> <p>Only one trial assessed contrast sensitivity (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>). </p> </section> <section id="CD004239-sec-0057"> <p><b>Change in quality of life</b></p> <p>None of the included trials measured this outcome.</p> </section> </section> </section> </section> <section id="CD004239-sec-0058"> <h4 class="title">Excluded studies</h4> <p>The previous review (<a href="./references#CD004239-bbs2-0062" title="SivaprasadS , BunceC , JyothiS . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub2]">Sivaprasad 2004</a>), excluded nine trials (<a href="./references#CD004239-bbs2-0011" title="AhluwaliaBK , KalraSC , ParmarIP , KhuranaAK . A comparative study of the effect of antiprostaglandins and steroids on aphakic cystoid macular oedema. Indian Journal of Ophthalmology1988;36(4):176-8. ">Ahluwalia 1988</a>; <a href="./references#CD004239-bbs2-0013" title="AzzoliniC , BressanP , DorigoMT . Medical treatment of cystoid macular oedema in aphakia patients. Minerva Oftalmologica1986;28(1):15-20. ">Azzolini 1986</a>; <a href="./references#CD004239-bbs2-0015" title="Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long-term cystoid macular edema. Journal of Cataract and Refractive Surgery1997;23(8):1183-9. ">IDSG 1997</a>; <a href="./references#CD004239-bbs2-0016" title="JampolLM , JainS , PudziszB , WeinrebRN . Nonsteroidal anti-inflammatory drugs and cataract surgery. Archives of Ophthalmology1994;112(7):891-4. ">Jampol 1994</a>; <a href="./references#CD004239-bbs2-0017" title="KraffMC , SandersDR , JampolLM , LiebermanHL . Factors affecting pseudophakic cystoid macular edema: five randomized trials. American Intra-Ocular Implant Society Journal1985;11:380-5. ">Kraff 1985</a>; <a href="./references#CD004239-bbs2-0019" title="MiyakeK . Nonsteroidal anti-inflammatory agents in cataract intraocular lens surgery. Current Opinion of Ophthalmology1995;6(1):62-5. ">Miyake 1995</a>; <a href="./references#CD004239-bbs2-0023" title="RossettiL , BujtarE , CastoldiD , TorrazzaC , OrzalesiN . Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery1996;22 Suppl 1:794-9. ">Rossetti 1996</a>; <a href="./references#CD004239-bbs2-0024" title="SingalN , HopkinsJ . Pseudophakic cystoid macular edema: ketorolac alone vs. ketorolac plus prednisolone. Canadian Journal of Ophthalmology2004;39(3):245-50. ">Singal 2004</a>; <a href="./references#CD004239-bbs2-0025" title="Stark WJ Jr, MaumeneeAE , FagadauW , DatilesM , BakerCC , WorthenD , et al. Cystoid macular edema in pseudophakia. Survey of Ophthalmology1984;28 Suppl:442-51. ">Stark 1984</a>) because they either tested NSAIDs for prophylactic purposes or tested efficacy of prednisolone, rather than an NSAID. The prior review update (<a href="./references#CD004239-bbs2-0064" title="SivaprasadS , BunceC , Crosby-NwaobiR . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub3]">Sivaprasad 2012</a>) further excluded four trials (<a href="./references#CD004239-bbs2-0012" title="AsanoS , MiyakeK , OtaI , SugitaG , KimuraW , SakkaY , et al. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive Surgery2008;34(1):57-63. ">Asano 2008</a>; <a href="./references#CD004239-bbs2-0018" title="MathysKC , CohenKL . Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye2010;24(1):90–6. ">Mathys 2010</a>; <a href="./references#CD004239-bbs2-0020" title="MiyakeK , NishimuraK , HarinoS , OtaI , AsanoS , KondoN , et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology and Visual Science2007;48(12):5647–52. ">Miyake 2007</a>; <a href="./references#CD004239-bbs2-0026" title="WarrenKA , BahraniH , FoxJE . NSAIDS in combination therapy for the chronic pseudophakic cystoid macular edema. Retina2010;30(2):260–6. ">Warren 2010</a>).  </p> <p>For the current update, we excluded three trials that were not RCTs (<a href="./references#CD004239-bbs2-0010" title="AaronsonA , AchironA , TuuminenR . Clinical course of pseudophakic cystoid macular edema treated with nepafenac. Journal of Clinical Medicine2020;9(9):3034. ">Aaronson 2020</a>; <a href="./references#CD004239-bbs2-0014" title="GinsburgAP , CheethamJK , DeGryseRE , AbelsonM . The effects of flurbiprofen and indomethacin on acute cystoid macular edema: functional vision and contrast sensitivity. Investigative Ophthalmology &amp; Visual Science1994;35:Abstract number 1153. ">Ginsburg 1994</a>; <a href="./references#CD004239-bbs2-0027" title="WolfensbergerTJ , HerbortCP . Treatment of cystoid macular edema with non-steroidal anti-inflammatory drugs and corticosteroids. Documenta Ophthalmologica. Advances in Ophthalmology1999;97(3-4):381-6. ">Wolfensberger 1999</a>); one that examined effects of topical steroid (<a href="./references#CD004239-bbs2-0022" title="NCT01769352. Treatment of post-surgical cystoid macular edema with topical steroids trial (TEMPEST-1). ClinicalTrials.gov/show/NCT01769352 (first received 16 January 2013). ">NCT01769352</a>); and one trial that was withdrawn before enrolling participants (<a href="./references#CD004239-bbs2-0021" title="NCT00438243. Pilot study of the effect of topical bromfenac ophthalmic solution 0.09%in patients with acute post-operative cystoid macular edema. ClinicalTrials.gov/show/NCT00438243 (first received 22 February 2007). ">NCT00438243</a>). Overall, we excluded 18 trials, as documented in the <a href="./references#CD004239-sec-0137" title="">Characteristics of excluded studies</a>.  </p> </section> </section> <section id="CD004239-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>In this update, we applied the Cochrane risk of bias tool to assess the quality of the two newly‐added trials (<a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>), as well as the seven trials included in the previous review (<a href="./references#CD004239-bbs2-0064" title="SivaprasadS , BunceC , Crosby-NwaobiR . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub3]">Sivaprasad 2012</a>). We did not deem any of the included nine trials as low risk across all bias domains (<a href="#CD004239-fig-0002">Figure 2</a>). We assessed three trials (<a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>) as having unclear risk of bias overall (33%) and the other six as having high (67%) risk of bias (see <a href="#CD004239-fig-0003">Figure 3</a> for risk of bias items presented as percentages). </p> <div class="figure" id="CD004239-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD004239-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD004239-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD004239-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD004239-sec-0060"> <h4 class="title">Allocation</h4> <section id="CD004239-sec-0061"> <h5 class="title">Random sequence generation </h5> <p>Three trials used computer‐generated random sequences for the randomization process, which we deemed at low risk of bias (<a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>). One trial used centralized randomization by a pharmacy, but did not state their method of sequence generation, so we deemed it at unclear risk of bias (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>). The trial authors of the remaining five trials stated that the groups were randomly allocated, but the method of treatment assignment was unclear, so we deemed these trials at unclear risk of bias (56%; <a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>; <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>; <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>; <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>). </p> </section> <section id="CD004239-sec-0062"> <h5 class="title">Allocation concealment before assignment</h5> <p><a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a> distributed treatment "in a double‐masked fashion", so we deemed this trial to be at low risk of bias (11%). In <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>, the "randomization was performed by the pharmacy that supplied the premasked medications", suggesting that the pharmacy might have had the knowledge of the corresponding sequences of randomization and medications; we deemed this trial at high risk of bias (11%). The other seven trials did not describe how they concealed allocation, and we deemed them at unclear risk of bias (78%; <a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>; <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>; <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>; <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>).  </p> </section> </section> <section id="CD004239-sec-0063"> <h4 class="title">Blinding</h4> <section id="CD004239-sec-0064"> <h5 class="title">Masking of participants and personnel</h5> <p>All of the included trials, except <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>, <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> and <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>, were double‐masked and we deemed them to be at low risk of bias (67%). <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a> and <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a> did not report on masking, and we deemed them at unclear risk of bias (22%). In <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>, the medication bottles were unmasked; we deemed this trial at high risk of bias for this domain (11%). </p> </section> <section id="CD004239-sec-0065"> <h5 class="title">Masking of outcome assessment</h5> <p>Four of the nine trials were reportedly "double‐masked" for both study participants and clinical investigators or examiners; we deemed these to be at low risk of bias (50%; <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>). In <a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a> and <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>, it was not clear whether or not all examiners and trial personnel performing and interpreting ocular examinations at follow‐up visits were masked; thus, we deemed these two trials at unclear risk of bias. <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a> and <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a> did not report on masking and we also deemed them at unclear risk of bias (44%). In <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>, the medication bottles were unmasked; we deemed this trial at high risk of bias for this domain (11%). </p> </section> </section> <section id="CD004239-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>Seven of the included nine trials reported outcome data for all or nearly all randomized participants; we deemed these trials at low risk of bias (78%; <a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>; <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>; <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>). We deemed <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a> and <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> as having unclear risk of bias: <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a> excluded substantial proportions of participants (25% in the intervention group and 17% in the placebo group) from the analysis due to loss to follow‐up; <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> did not report the group‐specific follow‐up rates nor the planned study duration.  </p> </section> <section id="CD004239-sec-0067"> <h4 class="title">Selective reporting</h4> <p>We deemed five trials to be at low risk of bias because they reported all of their prespecified outcomes (56%; <a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>; <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>). We judged three trials to be at unclear risk of bias (<a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>; <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>) because no trial protocol or detailed methods description was available for assessment. We also deemed <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a> to be at unclear risk of bias because the authors did not clearly report FFA results in a conventional way and the unit of analysis was the eye, while the unit of randomization was the person.  </p> </section> <section id="CD004239-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>We deemed five of the nine trials to be at unclear risk of bias (56%; <a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>). Although the respective trials were supported, at least in part, by industry, the trial authors did not report or disclose relevant conflicts of interest. We also deemed <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a> to be at unclear risk of bias although the author reported that he had no financial or proprietary interest "in any material or method mentioned"; the author was on the speaker's bureau of a company that made one of the drugs investigated in the trial. Similarly, we deemed <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a> to be at unclear risk of bias because the first author served as a consultant for the same company that funded the trial. We deemed <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> and <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a> to be at high risk of bias because the first author of these publications reported a commercial relationship with a company that made one of the drugs investigated in each of these trials. </p> </section> </section> <section id="CD004239-sec-0069"> <h3 class="title" id="CD004239-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD004239-tbl-0001"><b>Summary of findings 1</b> NSAID versus placebo or active control in acute cystoid macular edema</a>; <a href="./full#CD004239-tbl-0002"><b>Summary of findings 2</b> NSAID versus placebo in chronic cystoid macular edema</a>; <a href="./full#CD004239-tbl-0003"><b>Summary of findings 3</b> NSAID versus active control in mixed cystoid macular edema</a> </p> <section id="CD004239-sec-0070"> <h4 class="title">Comparison 1: NSAID versus placebo or active control in participants with acute CME</h4> <p>Three of the nine included trials enrolled participants whose CME had been diagnosed within four months before study entry (<a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>). <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a> compared topical ketorolac with placebo whereas the other two trials (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>; <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a>) compared topical ketorolac with one or more active treatments. See <a href="./full#CD004239-tbl-0001">summary of findings Table 1</a> showing findings of trials comparing NSAIDs with placebo or active control in participants with acute CME.  </p> <section id="CD004239-sec-0071"> <h5 class="title">Critical outcomes</h5> <section id="CD004239-sec-0072"> <h6 class="title">Improvement of two or more lines in Snellen visual acuity or equivalent at end of treatment </h6> <p>Two of the three trials reported on improvement in Snellen visual acuity of two or more lines at the end of treatment (<a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>; <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>).   </p> <p>In <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a>, after the first 30‐day treatment period in this cross‐over study (22 participants), a two‐line visual acuity improvement was achieved in 4 of 11 (36%) participants treated with topical ketorolac tromethamine 0.5% and 2 of 11 (18%) participants in the placebo group, suggesting that there was no treatment benefit of ketorolac on visual improvement compared with placebo (RR 2.00, 95% CI 0.46 to 8.76;  <a href="#CD004239-fig-0004">Figure 4</a>). The authors also reported seven‐year outcomes of the 22 participants included in the study, demonstrating improved vision without additional medical or surgical treatment at the time of their last examination in all but two participants, whose decreased vision was unrelated to CME (anterior ischemic optic neuropathy in one participant, glaucoma in the other).  </p> <div class="figure" id="CD004239-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison1: NSAID versus placebo or active control in acute CME, outcome 1.1 Proportion of participants with visual improvement" data-id="CD004239-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison1: NSAID versus placebo or active control in acute CME, outcome 1.1 Proportion of participants with visual improvement </p> </div> </div> </div> <p>In the three‐arm trial (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>), participants were treated until the CME resolved or for three months before tapering. When compared with topical prednisolone acetate 1.0%, topical ketorolac tromethamine 0.5% may have little or no effect on visual acuity improvement (RR 1.33, 95%: 0.58 to 3.07; 17 participants). Similarly, ketorolac 0.5% and prednisolone 1.0% combination therapy may not increase or decrease the likelihood of improved visual acuity when compared with prednisolone alone (RR 1.78, 95% CI 0.86 to 3.69; 18 participants; <a href="#CD004239-fig-0004">Figure 4</a>). The trial authors further compared visual acuity improvement in Snellen lines (<a href="./references#CD004239-fig-0009" title="">Analysis 1.2</a>), but found inconsistent results. Ketorolac had little or no effect on visual improvement (MD 0.80 Snellen lines, 95% CI 0.08 to 1.52; 18 participants) when compared with prednisolone alone. In contrast, the combination therapy was associated with an improvement in visual acuity of 2.70 more lines (95% CI 1.99 to 3.41; 17 participants) than was observed with prednisolone alone at three months.  </p> <p>Instead of reporting visual acuity improvement from baseline, <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a> found no differences within 26 weeks in the mean final visual acuity between the ketorolac and diclofenac groups among all study participants (20/58 versus 20/49, P = 0.74; 34 participants), in the subgroup of participants who experienced CME reduction (20/30 versus 20/30, P = 1.0), and in the subgroup of participants with complete resolution of CME (20/25 versus 20/25, P = 1.0).  </p> <p>Overall, when compared with placebo or active treatment, the evidence on the treatment effects of ketorolac 0.5% on visual acuity improvement at the end of treatment is very uncertain. The certainty level of the evidence for this outcome was very low after we downgraded it for risk of bias, imprecision, and inconsistency.  </p> </section> <section id="CD004239-sec-0073"> <h6 class="title">Persistence of improvement of vision one month after discontinuation of treatment</h6> <p>None of the included trials reported this outcome.</p> </section> </section> <section id="CD004239-sec-0074"> <h5 class="title">Important outcomes</h5> <section id="CD004239-sec-0075"> <h6 class="title">Proportion of participants with improvement in leakage on FFA</h6> <p><a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a> observed improvement in leakage on FFA in 5 of 9 (55%) participants treated with ketorolac tromethamine 0.5%, 4 of 8 participants (50%) treated with prednisolone acetate 1.0%, and 7 of 9 participants (77%) treated with ketorolac and prednisolone combination therapy. When compared with prednisolone alone (RR 1.11, 95% CI 0.45 to 2.75; 17 participants) or with combination therapy (RR 1.56, 95% CI 0.72 to 3.38; 17 participants), we found no evidence that ketorolac had additional treatment benefits (<a href="./references#CD004239-fig-0010" title="">Analysis 1.3</a>). The certainty of the evidence for this outcome was very low after we downgraded it for risk of bias, imprecision, and heterogeneity. </p> </section> <section id="CD004239-sec-0076"> <h6 class="title">Proportion of participants with improvement in central macular thickness on OCT</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD004239-sec-0077"> <h6 class="title">Proportion of participants with improved contrast sensitivity</h6> <p><a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a> found improvement in contrast sensitivity in 5 of 9 participants (55%) treated with ketorolac tromethamine 0.5%, 4 of 8 participants (50%) treated with prednisolone acetate 1.0%,  and 8 of 9 of participants (89%) treated with ketorolac and prednisolone combination therapy. When compared with prednisolone alone (RR 1.11, 95% CI 0.45 to 2.75; 17 participants) or with combination therapy (RR 1.78, 95% CI 0.86 to 3.69; 17 participants), there was no evidence that ketorolac had additional treatment benefits (<a href="./references#CD004239-fig-0011" title="">Analysis 1.4</a>). The certainty of the evidence for this outcome was very low after we downgraded it for risk of bias, imprecision, and heterogeneity. </p> </section> <section id="CD004239-sec-0078"> <h6 class="title">Change in quality of life</h6> <p>None of the included trials reported this outcome.</p> </section> </section> <section id="CD004239-sec-0079"> <h5 class="title">Other outcomes reported by the included trials </h5> <section id="CD004239-sec-0080"> <h6 class="title">Improvement or reduction of CME by biomicroscopic examination </h6> <p><a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a> repeatedly assessed participants for severity of CME by Goldmann contact lens biomicroscopy during the follow‐up period. FFA "was repeated if clinical CME persisted". At the end of the 26‐week treatment, there was no evidence that diclofenac may have effects on completely resolving CME (RR 1.04, 95% CI 0.71 to 1.51; 34 participants) when compared to ketorolac (<a href="./references#CD004239-fig-0012" title="">Analysis 1.5</a>). The authors also concluded that reported time (in weeks) to CME reduction was comparable in the ketorolac (mean 8.0, standard deviation [SD] 1.8) and diclofenac groups (mean 7.5, SD 1.5). </p> </section> </section> <section id="CD004239-sec-0081"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a> reported that "there were no complaints about burning or stinging following eyedrop instillation and "none of the patients developed any signs of ocular toxicity during the study." <a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a> found no adverse events of superficial punctate keratitis, allergic reaction, or other ocular changes "that prevented [patients] from completing the study". <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a> did not mention any adverse events associated with the intervention treatments. </p> </section> </section> <section id="CD004239-sec-0082"> <h4 class="title">Comparison 2: NSAID versus placebo in participants with chronic CME</h4> <p>Four of the nine included trials enrolled participants whose CME had been diagnosed for at least four months prior to the study entry (<a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>; <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a>; <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>). See <a href="./full#CD004239-tbl-0002">summary of findings Table 2</a> for review findings of trials comparing NSAIDs versus placebo in participants with chronic CME.  </p> <section id="CD004239-sec-0083"> <h5 class="title">Critical outcomes</h5> <section id="CD004239-sec-0084"> <h6 class="title">Improvement of two or more lines in Snellen visual acuity or equivalent at end of treatment </h6> <p>All four trials reported an improvement in Snellen visual acuity of two or more lines at the end of treatment. </p> <p><a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a> compared topical fenoprofen sodium 1% (6 participants) with placebo (8 participants). At the end of the eight‐week treatment period, an improvement of two or more lines in Snellen visual acuity was similarly achieved in the fenoprofen group compared with the placebo group (RR 1.33, 95% CI 0.40 to 4.43).  </p> <p><a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a> randomized 30 eyes of 30 patients to treatment with either topical ketorolac tromethamine 0.5% or placebo, four times daily for no more than 90 days. Four participants failed to complete the study: one participant was lost to follow‐up and another developed an ocular allergy in the ketorolac group; two participants in the placebo group did not complete the study due to poor compliance and myocardial infarction, respectively. Eight of 13 participants (62%) In the ketorolac group and 1 of 13 participants (8%) in the placebo group, achieved an improvement of two or more lines of Snellen visual acuity at day 60, showing an increased likelihood of visual improvement when treated with NSAIDs versus placebo (RR 8.00, 95% CI 1.16 to 55.2; 26 participants). </p> <p><a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a> randomized 120 eyes of 120 patients to either topical ketorolac tromethamine 0.5% or placebo, four times a day for no more than 120 days. However, only 46 of the 61 participants (75%) enrolled in the ketorolac group and 49 of the 59 participants (83%) enrolled in the placebo group were examined at day 90 or day 120, depending on results of distance visual acuity at day 90. By three months of treatment, 48% and 20% of the returning participants in the ketorolac group and placebo group, respectively, had a visual acuity improvement of two lines or more (RR 2.34, 95% CI 1.25 to 4.40; 95 participants).   </p> <p><a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a> randomized 20 participants (23 eyes) to receive either 25 mg of orally administered indomethacin three times per day (10 participants, 10 eyes) or placebo three times per day (10 participants, 13 eyes) for six weeks. Participants were re‐assessed at weeks 3, 6, and 10. At the end of treatment (week 6), 2 of 10 (20%) eyes in the indomethacin group and 4 of 13 (31%) eyes in the placebo group had achieved an improvement of two or more lines in Snellen visual acuity; the estimated treatment effect at the person level was RR 0.40 (95% CI 0.10 to 1.60; 20 participants) comparing indomethacin with placebo. </p> <p>Because of evidence of subgroup differences (P = 0.01, I<sup>2</sup> = 84.7%), we did not combine estimates from trials that had treated participants with different durations of therapy (<a href="./references#CD004239-fig-0013" title="">Analysis 2.1</a>). Results from subgroups suggested that NSAIDs may increase participants' likelihood of visual improvement by 1.87 fold (RR 2.87, 95% CI 1.58 to 5.22; I<sup>2</sup> = 33%; 2 trials, 121 participants) relative to placebo after treatment of 90 days or longer; however, there was no evidence of treatment effect of NSAID  in the subgroup with two months or shorter use of NSAID (RR 0.72, 95% CI 0.30 to 1.73; P = 0.19, I<sup>2</sup> = 41%; 2 trials, 34 participants; <a href="#CD004239-fig-0005">Figure 5</a>).  </p> <div class="figure" id="CD004239-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.1 Proportion of participants with visual improvement" data-id="CD004239-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.1 Proportion of participants with visual improvement </p> </div> </div> </div> <p>In a post‐hoc sensitivity analysis that excluded a trial that had examined oral indomethacin (<a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>), the between‐group heterogeneity attenuated (P = 0.30, I<sup>2</sup> = 7.9%), and the combined results suggested that topical NSAIDs may increase participants' visual improvement as compared to placebo (RR 2.33, 95% CI 1.17 to 4.66; I<sup>2</sup> = 22%; 3 trials, 135 participants; <a href="./references#CD004239-fig-0014" title="">Analysis 2.2</a>). </p> <p>Overall, the certainty level of the evidence for this outcome was very low after we downgraded it for risk of bias, imprecision, and heterogeneity. </p> </section> <section id="CD004239-sec-0085"> <h6 class="title">Persistence of improvement of vision one month after discontinuation of treatment</h6> <p><a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a> reported persistence of visual acuity at one month following cessation of treatment. Two eyes of two participants in the indomethacin group and five eyes of five participants in the placebo group that had improved by two or more lines of vision after 6 weeks of treatment still maintained at least a two‐line visual acuity improvement one month following cessation of treatment (at day 70). The single‐study estimate for oral NSAID was RR 0.40 (95% CI 0.10 to 1.60; 20 participants) when compared to placebo. Similarly, in <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>, four of the eight participants in the ketorolac group and one participant in the placebo group who achieved visual improvement at the end of the 60‐day treatment period still maintained two lines or more of visual improvement on day 90. The single‐study estimate was equivocal (RR 4.00, 95% CI 0.51 to 31.13; 26 participants). Although we did not combine results of these two trials due to between‐group heterogeneity (P = 0.07, I<sup>2</sup> = 69.9%), overall, the  estimate of either subgroup suggests that NSAIDs had no effect on persistent visual improvement one month after the treatment ended (<a href="#CD004239-fig-0006">Figure 6</a>). The certainty of the evidence for this outcome was very low, downgraded one level due to risk of bias and two levels due to extreme imprecision.  </p> <div class="figure" id="CD004239-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.2 Proportion of participants with persistent visual improvement one month after discontinuation of treatment" data-id="CD004239-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.2 Proportion of participants with persistent visual improvement one month after discontinuation of treatment </p> </div> </div> </div> </section> </section> <section id="CD004239-sec-0086"> <h5 class="title">Important outcomes</h5> <section id="CD004239-sec-0087"> <h6 class="title">Proportion of participants with improvement in leakage on FFA</h6> <p>Two of  the four trials reported on this outcome (<a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a>; <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a>; <a href="./references#CD004239-fig-0016" title="">Analysis 2.4</a>). <a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a> observed decreased leakage on FFA in three participants in each of the fenoprofen (6 participants, 50%) and placebo groups (8 participants, 38%), corresponding to a single‐study estimated RR of 1.33 (95% CI 0.40 to 4.43). <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a> observed decreased leakage on FFA in two of the 13 participants (15%) receiving ketorolac and none in the placebo group (13 participants). The combined estimate of RR for improvement in leakage on FFA was 1.93 (95% CI 0.62 to 6.02, 40 participants), indicating that NSAIDs had little to no beneficial effect over placebo (I<sup>2</sup> = 0%; <a href="#CD004239-fig-0007">Figure 7</a>). The certainty level of the evidence for this outcome was very low after downgrading for risk of bias (−1) and extreme imprecision (−2). </p> <div class="figure" id="CD004239-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.3 Proportion of participants with improved FFA" data-id="CD004239-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.3 Proportion of participants with improved FFA </p> </div> </div> </div> </section> <section id="CD004239-sec-0088"> <h6 class="title">Proportion of participants with improvement in central macular thickness on OCT</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD004239-sec-0089"> <h6 class="title">Proportion of participants with improved contrast sensitivity</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD004239-sec-0090"> <h6 class="title">Change in quality of life</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD004239-sec-0091"> <h6 class="title">Other outcomes reported by the included trials</h6> <section id="CD004239-sec-0092"> <p><b>Proportion of participants with complete resolution of CME</b></p> <p><a href="./references#CD004239-bbs2-0001" title="BurnettJ , TesslerH , IsenbergS , TsoMO . Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surgery1983;14(2):150-2. ">Burnett 1983</a> reported that there was no leakage on FFA at the final study visit in one of the six participants (17%) in the fenoprofen group and one of the eight participants (13%) in the placebo group after eight weeks of treatment with fenoprofen 1% versus placebo (<a href="./references#CD004239-fig-0017" title="">Analysis 2.5</a>).  </p> </section> </section> </section> <section id="CD004239-sec-0093"> <h5 class="title">Adverse events</h5> <p>Across trials, one participant in <a href="./references#CD004239-bbs2-0002" title="FlachAJ , DolanBJ , IrvineAR . Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology1987;103(4):479-86. ">Flach 1987</a> assigned to treatment with ketorolac did not complete the study due to ocular allergy. <a href="./references#CD004239-bbs2-0003" title="FlachAJ , JampolLM , WeinbergD , KraffMC , YannuzziLA , CampoRV , et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology1991;112(5):514-9. FlachAJ . Visual improvement in patients with chronic aphakic and pseudophakic cystoid macular edema (ACME) following a topically applied cyclooxygenase inhibitor (COI)-ketorolac tromethamine 0.5% ophthalmic solution. Report of a multi-center study. Investigative Ophthalmology &amp; Visual Science1991;32:ARVO abstract 91. ">Flach 1991</a> reported that there were no statistically significant differences in the number or severity of adverse events between treatment groups.  </p> </section> </section> <section id="CD004239-sec-0094"> <h4 class="title">Comparison 3: NSAID versus active control in participants with mixed duration of CME</h4> <p>Two trials did not specify the types (or durations) of CME in the inclusion criteria for the primary study (<a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>; <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>). See <a href="./full#CD004239-tbl-0003">summary of findings Table 3</a> for review findings comparing NSAID versus active treatments in participants with probably mixed types of CME. </p> <section id="CD004239-sec-0095"> <h5 class="title">Critical outcomes</h5> <section id="CD004239-sec-0096"> <h6 class="title">Improvement of two or more lines in Snellen visual acuity or equivalent at end of treatment </h6> <p>One trial reported an improvement in Snellen visual acuity of two or more lines at the end of treatment (<a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a>). <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> was a two‐arm trial that randomized 68 eyes of 68 patients to topical diclofenac sodium 0.1% or topical ketorolac tromethamine 0.5%. Both comparison groups were also provided with topical prednisolone acetate 0.1%. All participants reportedly completed at least three months of treatment yet the exact follow‐up duration was not reported. Based on the single‐study estimate, diclofenac + prednisolone may increase participants' likelihood of visual improvement by 40% when compared to ketorolac + prednisolone (RR 1.40, 95% CI 1.02 to 1.94; 68 participants; <a href="./references#CD004239-fig-0018" title="">Analysis 3.1</a>).  </p> <p><a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> also reported visual acuity improvement in Snellen lines (<a href="./references#CD004239-fig-0019" title="">Analysis 3.2</a>). However, the single‐study estimate showed no effect of diclofenac over ketorolac in increasing or decreasing Snellen lines of visual acuity at the end of treatment (MD 0.40, 95% CI −0.93 to 1.73; 68 participants).  </p> <p>Similarly, <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a> reported visual improvement in ETDRS letters when participants completed the study at three months. <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a> randomized 52 eyes of 52 patients to one of three regimens: topical bromfenac 0.09% twice daily, topical diclofenac sodium 0.0.1% four times daily, or topical ketorolac tromethamine 0.05% four times daily. The single‐study estimates showed that either diclofenac (MD 0.90, 95% CI −4.31 to 6.11 ETDRS letters; 34 participants) or bromfenac alone (MD 1.20, 95% CI −4.58 to 6.98 ETDRS letters; 34 participants) had no effect on visual improvement  (<a href="./references#CD004239-fig-0020" title="">Analysis 3.3</a>).  </p> <p>Overall, NSAID may slightly increase participants' likelihood of visual improvement but the evidence is very uncertain. The certainty of the evidence for this outcome was very low because we downgraded it for risk of bias, imprecision, and inconsistency (<a href="./full#CD004239-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD004239-sec-0097"> <h6 class="title">Persistence of visual improvement of vision one month after discontinuation of treatment</h6> <p>None of the included trials reported this outcome.</p> </section> </section> <section id="CD004239-sec-0098"> <h5 class="title">Important outcomes</h5> <section id="CD004239-sec-0099"> <h6 class="title">Proportion of participants with improvement in leakage on FFA</h6> <p>None of the included trials reported this outcome. </p> </section> <section id="CD004239-sec-0100"> <h6 class="title">Proportion of participants with improvement in central macular thickness on OCT</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD004239-sec-0101"> <h6 class="title">Proportion of participants with improved contrast sensitivity</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD004239-sec-0102"> <h6 class="title">Change in quality of life</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD004239-sec-0103"> <h6 class="title">Other outcomes reported by the included trials</h6> <section id="CD004239-sec-0104"> <p><b>Complete resolution of CME by unspecified measurement or examination</b></p> <p><a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> reported complete resolution of CME without specifying how it was determined. <a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> observed that 10 of 36 participants (28%) in the diclofenac group and 8 of 32 participants (25%) in the ketorolac group achieved complete resolution of CME. The single‐study estimate suggests that diclofenac had no or little effect on CME resolution (RR 1.11, 95% CI 0.50 to 2.47; 68 participants; <a href="./references#CD004239-fig-0021" title="">Analysis 3.4</a>) when compared with another NSAID (ketorolac). </p> </section> </section> <section id="CD004239-sec-0105"> <h6 class="title">Adverse events</h6> <p><a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> stated that none of the participants "showed signs of corneal toxicity or significant intraocular pressure rise during the treatment period." There was no mention of ocular adverse events in <a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a>.  </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004239-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004239-sec-0106"></div> <section id="CD004239-sec-0107"> <h3 class="title" id="CD004239-sec-0107">Summary of main results</h3> <p>We based our findings on data from nine RCTs that investigated the effectiveness of any form or dosage of NSAIDs compared to placebo, no treatment or another active treatment modality, including different types of NSAIDs, with the aim of treating CME following cataract surgery. NSAIDs may not improve visual acuity at the end of treatment for any type of CME. Although there was evidence that NSAIDs may slightly increase the likelihood of visual acuity improvement with 90 days or longer of treatment for patients with chronic CME, the overall evidence was very uncertain (very low‐certainty evidence). We did not find evidence that NSAIDs had an effect on persistent visual improvement after treatment discontinuation (very low‐certainty evidence); improvement of leakage on FFA (very low‐certainty evidence); or improvement in contrast sensitivity (very low‐certainty evidence). None of the included trials reported on improvement in central macular thickness on OCT or change in quality of life. Thus, this review found that evidence on the effects of NSAIDs in acute or chronic CME is very uncertain and further investigation is warranted. </p> </section> <section id="CD004239-sec-0108"> <h3 class="title" id="CD004239-sec-0108">Overall completeness and applicability of evidence</h3> <p>The findings of this review may be applicable to patients with CME of various durations after cataract surgery. However, because the majority of the included primary studies excluded high‐risk patients (those with pre‐existing macular disease, poorly controlled diabetes or hypertension), our review findings are not generalizable to such individuals. In addition, our findings are limited by small sample sizes of primary studies, a deficient number of eligible trials reporting on the same outcomes, heterogeneity in interventions (varying treatment medications or durations) and different follow‐up durations.   </p> <p>Further, the publication dates of the trials included in this review range from 1977 to 2006, and there have been many advancements in cataract surgery techniques throughout and since that time. For example, cataract surgery has progressed from intracapsular cataract extraction to extracapsular cataract extraction to phacoemulsification cataract surgery; from large sutured wounds to small, nonsutured wounds; from scleral to corneal incisions; and from retrobulbar or peribulbar anesthesia to topical anesthesia (<a href="./references#CD004239-bbs2-0033" title="DavisG . The evolution of cataract surgery. Missouri Medicine2016;113(1):58-62.">Davis 2016</a>; <a href="./references#CD004239-bbs2-0035" title="FichmanRA . Use of topical anesthesia alone in cataract surgery. Journal of Cataract and Refractive Surgery1996;22(5):612-4.">Fichman 1996</a>). Advancements in cataract surgery may lead to differences in the underlying risks of developing CME postoperatively over time. However, several published studies indicate that, even after the many advancements in cataract surgery techniques, the rate of clinically significant CME following modern cataract surgery is about 2% (<a href="./references#CD004239-bbs2-0045" title="KesselL , TendalB , JørgensenKJ , ErngaardD , FlesnerP , AndresenJL , et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology2014;121(10):1915-24.">Kessel 2014</a>; <a href="./references#CD004239-bbs2-0047" title="MalwankarJ , SonHS , ChangDF , DunC , WoretaF , PrescottC , et al. Trends, factors, and outcomes associated with immediate sequential bilateral cataract surgery among Medicare beneficiaries. Ophthalmology2022;129(5):478-87.">Malwankar 2022</a>; <a href="./references#CD004239-bbs2-0059" title="TaipaleC , HolmströmEJ , IlveskoskiL , TuuminenR . Incidence of pseudophakic cystoid macular edema in eyes with and without pupil expansion device. Acta Ophthalmologica2019;97(7):688-94.">Taipale 2019</a>). The lack of a placebo group across CME types prohibited us from inferring any overall treatment benefits of NSAIDs and from distinguishing treatment effect from spontaneous resolution of CME. </p> <p>It should also be noted that most of the trials included in this review were performed before the widespread use of OCT (<a href="./references#CD004239-bbs2-0036" title="FujimotoJ , SwansonE . The development, commercialization, and impact of optical coherence tomography. Investigative Ophthalmology &amp; Visual Science2016;57:OCT1-OCT13. [DOI: 10.1167/iovs.16-19963]">Fujimoto 2016</a>). Due to its non‐contact and non‐invasive approach, quick image acquisition, high‐resolution images, and safety profile, OCT has become a leading diagnostic imaging modality for pseudophakic CME (<a href="./references#CD004239-bbs2-0060" title="TrichonasG , KaiserPK . Optical coherence tomography imaging of macular oedema. British Journal of Ophthalmology2014;98:ii24-ii29.">Trichonas 2014</a>), although in some cases, obtaining FFA imaging may be useful in differentiating pseudophakic CME from other conditions such as diabetic macular edema.   </p> <p>Moreover, standards of conducting and reporting intervention trials have evolved over time, particularly since the publication of the first CONSORT (Consolidated Standards of Reporting Trials) Statement in 1996 (<a href="./references#CD004239-bbs2-0030" title="BeggC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA1996;276:637-9.">Begg 1996</a>). Inadequate reporting of participant characteristics and heterogeneity in the study design, such as the treatment duration, follow‐up duration, and frequency of outcome measurements (without clearly pre‐specified study endpoints), contributed to the generally low certainty of the evidence. In addition, the lack of consistent and valid methods for assessing and reporting outcomes created a barrier to synthesizing the evidence.  </p> </section> <section id="CD004239-sec-0109"> <h3 class="title" id="CD004239-sec-0109">Certainty of the evidence</h3> <p>None of the included nine trials was deemed as low risk across all bias domains; we assessed the majority of the trials as high risk of bias. We assessed most of the trials to be at unclear or high risk of bias on the random sequence generation and allocation concealment domains, and five of the trials at unclear or high risk of bias on the blinding of outcome assessment domain. Concerns in multiple bias domains, including unmasking of participants or assessors, substantial dropout rates, and selective outcome reporting, further downgraded the certainty level of the evidence for most, if not all, review outcomes. The evidence in the nine trials was very low certainty due to such factors as small sample sizes, poorly reported outcomes, inconsistent results, and the inability to distinguish drug effect from spontaneous resolution of CME. </p> </section> <section id="CD004239-sec-0110"> <h3 class="title" id="CD004239-sec-0110">Quality of the evidence</h3> <p>[left for empty]</p> </section> <section id="CD004239-sec-0111"> <h3 class="title" id="CD004239-sec-0111">Potential biases in the review process</h3> <p>We applied the standard Cochrane methods to conduct this update and avoided potential biases in the processes of literature search, critical appraisal, data extraction and entry, data analysis and interpretation. Although not always successful, we also contacted trial authors and publication authors to request clarification or detailed information regarding study design and outcome in attempts to reduce information bias. To reduce inter‐rater biases, two review authors also independently re‐assessed risk of bias in the seven eligible trials of the previous review (<a href="./references#CD004239-bbs2-0062" title="SivaprasadS , BunceC , JyothiS . Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD004239. [DOI: 10.1002/14651858.CD004239.pub2]">Sivaprasad 2004</a>). </p> </section> <section id="CD004239-sec-0112"> <h3 class="title" id="CD004239-sec-0112">Agreements and disagreements with other studies or reviews</h3> <p>A recently published systematic review, which investigated the effect of NSAIDs for acute and chronic CME (<a href="./references#CD004239-bbs2-0051" title="OrskiM , GawęckiM . Current management options in Irvine-Gass syndrome: a systemized review. Journal of Clinical Medicine2021;10(19):4375.">Orski 2021</a>), included seven trials, two of which were RCTs, and reported visual acuity improvement and central macular thickness reduction. However, similar to our review, the trials in that review were constrained by small sample sizes, as well as heterogeneity in interventions, treatment durations, follow‐up intervals, and outcome assessments. Because of these study limitations, the authors of <a href="./references#CD004239-bbs2-0051" title="OrskiM , GawęckiM . Current management options in Irvine-Gass syndrome: a systemized review. Journal of Clinical Medicine2021;10(19):4375.">Orski 2021</a> also concluded that the available evidence is insufficient to formulate strong conclusions regarding NSAIDs for the treatment of either acute or chronic CME following cataract surgery. </p> <p>Similarly, the American Academy of Ophthalmology (AAO) released an Ophthalmic Technology Assessment (OTA) regarding the use of topical NSAIDs after cataract surgery (<a href="./references#CD004239-bbs2-0046" title="KimSJ , SchoenbergerSD , ThorneJE , EhlersJP , YehS , BakriSJ . Topical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American Academy of Ophthalmology. Ophthalmology2015;122(11):2159-68.">Kim 2015</a>), and concluded that there was a lack of level I evidence to support the long‐term benefit of topical NSAIDs to prevent vision loss from CME at three months or more after cataract surgery. This OTA was based on a literature search of PubMed and the Cochrane Library in January 2015.  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004239-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD004239-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD004239-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD004239-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison1: NSAID versus placebo or active control in acute CME, outcome 1.1 Proportion of participants with visual improvement" data-id="CD004239-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison1: NSAID versus placebo or active control in acute CME, outcome 1.1 Proportion of participants with visual improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.1 Proportion of participants with visual improvement" data-id="CD004239-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.1 Proportion of participants with visual improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.2 Proportion of participants with persistent visual improvement one month after discontinuation of treatment" data-id="CD004239-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.2 Proportion of participants with persistent visual improvement one month after discontinuation of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.3 Proportion of participants with improved FFA" data-id="CD004239-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison 2: NSAID versus placebo in chronic CME, outcome 2.3 Proportion of participants with improved FFA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NSAID versus placebo or active control in acute CME, Outcome 1: Proportion of participants with visual improvement" data-id="CD004239-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: NSAID versus placebo or active control in acute CME, Outcome 1: Proportion of participants with visual improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NSAID versus placebo or active control in acute CME, Outcome 2: Improvement in VA, Snellen lines*" data-id="CD004239-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: NSAID versus placebo or active control in acute CME, Outcome 2: Improvement in VA, Snellen lines* </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NSAID versus placebo or active control in acute CME, Outcome 3: Proportion of participants with improved FFA" data-id="CD004239-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: NSAID versus placebo or active control in acute CME, Outcome 3: Proportion of participants with improved FFA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NSAID versus placebo or active control in acute CME, Outcome 4: Proportion of participants with improved contrast sensitivity" data-id="CD004239-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: NSAID versus placebo or active control in acute CME, Outcome 4: Proportion of participants with improved contrast sensitivity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NSAID versus placebo or active control in acute CME, Outcome 5: Proportion of participants with complete resolution*" data-id="CD004239-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: NSAID versus placebo or active control in acute CME, Outcome 5: Proportion of participants with complete resolution* </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NSAID versus placebo in chronic CME, Outcome 1: Proportion of participants with visual improvement" data-id="CD004239-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: NSAID versus placebo in chronic CME, Outcome 1: Proportion of participants with visual improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NSAID versus placebo in chronic CME, Outcome 2: Proportion of participants with visual improvement ‐ sensitivity analysis" data-id="CD004239-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: NSAID versus placebo in chronic CME, Outcome 2: Proportion of participants with visual improvement ‐ sensitivity analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NSAID versus placebo in chronic CME, Outcome 3: Proportion of participants with persistent visual improvement one month after discontinuation of treatment" data-id="CD004239-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: NSAID versus placebo in chronic CME, Outcome 3: Proportion of participants with persistent visual improvement one month after discontinuation of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NSAID versus placebo in chronic CME, Outcome 4: Proportion of participants with improved FFA" data-id="CD004239-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: NSAID versus placebo in chronic CME, Outcome 4: Proportion of participants with improved FFA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NSAID versus placebo in chronic CME, Outcome 5: Proportion of participants with complete resolution" data-id="CD004239-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: NSAID versus placebo in chronic CME, Outcome 5: Proportion of participants with complete resolution </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: NSAID versus active control in mixed CME, Outcome 1: Proportion of participants with visual improvement" data-id="CD004239-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: NSAID versus active control in mixed CME, Outcome 1: Proportion of participants with visual improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: NSAID versus active control in mixed CME, Outcome 2: Improvement in VA, Snellen lines*" data-id="CD004239-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: NSAID versus active control in mixed CME, Outcome 2: Improvement in VA, Snellen lines* </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: NSAID versus active control in mixed CME, Outcome 3: Improvement in VA, ETDRS letters*" data-id="CD004239-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: NSAID versus active control in mixed CME, Outcome 3: Improvement in VA, ETDRS letters* </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004239-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/urn:x-wiley:14651858:media:CD004239:CD004239-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: NSAID versus active control in mixed CME, Outcome 4: Proportion of participants with complete resolution*" data-id="CD004239-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_t/tCD004239-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: NSAID versus active control in mixed CME, Outcome 4: Proportion of participants with complete resolution* </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/media/CDSR/CD004239/image_n/nCD004239-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004239-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">NSAID versus placebo or active control in acute cystoid macular edema</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Non‐steroidal anti‐inflammatory drug vs placebo or active control for acute cystoid macular edema following cataract surgery</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient population:</b> participants with acute CME (&lt; 4 months) following cataract surgery </p> <p><b>Settings:</b> private clinics or medical centers in the USA </p> <p><b>Intervention:</b> ketorolac, diclofenac </p> <p><b>Comparison:</b> placebo, prednisolone, ketorolac + prednisolone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk*</b> </p> <p><b>Placebo or prednisolone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> <p><b>NSAID ± prednisolone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Visual improvement at end of treatment, as defined by two or more Snellen lines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b><br/>18 per 100  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac</b> </p> <p>36 (8 to 100) </p> <p>per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.00 (0.46 to 8.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RR &gt; 1 is better.</p> <p>Besides <a href="./references#CD004239-bbs2-0004" title="FlachAJ . The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Transactions of the American Ophthalmological Society1998;96:557-634. ">Flach 1998</a> (22 participants) and <a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a> (26 participants),  </p> <p><a href="./references#CD004239-bbs2-0006" title="RhoDS . Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery2003;29(12):2378-84. ">Rho 2003</a> (34 participants) compared mean final VA between participants receiving ketorolac with those receiving diclofenac (20/50 vs 20/49) and concluded no overall differences </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Prednisolone</b> </p> <p>50 per 100 </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac</b> </p> <p>67 (29 to 100)</p> <p>per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.33</p> <p>(0.58 to 3.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac + prednisolone</b> </p> <p>89 (43 to 100)</p> <p>per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.78</p> <p>(0.86 to 3.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of visual improvement one month after discontinuation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Improvement in leakage on FFA</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Prednisolone</b> </p> <p>50 per 100 </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac</b> </p> <p>56 (23 to 100) per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11</p> <p>(0.45 to 2.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR &gt; 1 is better.</p> <p>Data from the same 3‐arm trial (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac + prednisolone</b> </p> <p>78 (36 to 100) per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.56</p> <p>(0.72 to 3.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in central macular thickness on OCT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Improved contrast sensitivity</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Prednisolone</b> </p> <p>50 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac</b> </p> <p>56 (23 to 100) per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.11</p> <p>(0.45 to 2.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR &gt; 1 is better</p> <p>Data from the same 3‐arm trial (<a href="./references#CD004239-bbs2-0005" title="HeierJS , ToppingTM , BaumannW , DirksMS , ChernS , FlachAJ . Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology2000;107(11):2034-9. ">Heier 2000</a>) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac + prednisolone</b> </p> <p>89 (43 to 100) per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.78</p> <p>(0.86 to 3.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> <p>(1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and the associated 95% CI). </p> <p> </p> <p><b>CI:</b> confidence interval; <b>CME:</b> cystoid macular edema; <b>FFA:</b> fundus fluorescein angiography (angiogram); <b>NSAID:</b> non‐steroidal anti‐inflammatory drug; <b>OCT:</b> optical coherence tomography; <b>QoL:</b> quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias (‐1), imprecision (‐1) and heterogeneity (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">NSAID versus placebo or active control in acute cystoid macular edema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004239-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NSAID versus placebo in chronic cystoid macular edema</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Non‐steroidal anti‐inflammatory drug vs active control for chronic cystoid macular edema following cataract surgery</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient population:</b> participants with chronic CME (≥ 4 months) following cataract surgery </p> <p><b>Settings:</b> medical centers in the USA </p> <p><b>Intervention:</b> topical ketorolac, topical fenoprofen, oral indomethacin </p> <p><b>Comparison:</b> placebo (vehicle or saline) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk*</b> </p> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> <p><b>NSAID</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Visual improvement at end of treatment, as defined by two or more Snellen lines</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Treatment duration ≤ 2 months</b> </p> <p>44 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 (13 to 76) </p> <p>per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72</p> <p>(0.30 to 1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR &gt; 1 is better.</p> <p>When excluding <a href="./references#CD004239-bbs2-0009" title="YannuzziLA , KleinRM , WallynRH , CohenN , KatizI . Ineffectiveness of indomethacin in the treatment of chronic cystoid macular edema. American Journal of Ophthalmology1977;84(4):517-9. ">Yannuzzi 1977</a>, which examined oral NSAID, there was no evidence of subgroup differences and the combined RR was 2.33 (95% CI 1.17 to 4.66; 3 RCTs, 135 participants), favoring topical NSAIDs over placebo in visual improvement after at least 90 days of treatment. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Treatment duration 90‐120 days</b> </p> <p>18 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 (28 to 94) </p> <p>per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.87</p> <p>(1.58 to 5.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> <p>(2 RCTs)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of visual improvement one month after discontinuation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 (11 to 80)</p> <p>per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17</p> <p>(0.44 to 3.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in leakage on FFA</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 (9 to 84)</p> <p>per 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.93</p> <p>(0.62 to 6.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 is better.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in central macular thickness on OCT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not measured by any included trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improved contrast sensitivity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not measured by any included trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not measured by any included trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and the associated 95% CI). </p> <p> </p> <p><b>CI:</b> confidence interval; <b>CME:</b> cystoid macular edema; <b>FFA:</b> fundus fluorescein angiography (angiogram); <b>NSAID:</b> non‐steroidal anti‐inflammatory drug; <b>OCT:</b> optical coherence tomography; <b>QoL:</b> quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias (‐1), imprecision (‐1) and heterogeneity (‐1).<br/><sup>b</sup>Downgraded for risk of bias (‐1) and extreme imprecision (‐2). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">NSAID versus placebo in chronic cystoid macular edema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004239-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NSAID versus active control in mixed cystoid macular edema</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="bottom"> <p><b>Non‐steroidal anti‐inflammatory drug vs active control for cystoid macular edema following cataract surgery</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient population:</b> participants with acute or chronic CME following cataract surgery </p> <p><b>Settings:</b> private clinics in the USA or medical centers in Canada </p> <p><b>Intervention:</b> bromfenac, diclofenac ± prednisolone, ketorolac ± prednisolone </p> <p><b>Comparison:</b> ketorolac ± prednisolone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* </b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No. of participants</b> </p> <p><b>(RCTs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk*</b> </p> <p><b>Active control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> <p><b>NSAID</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Visual improvement at end of treatment, as defined by two or more Snellen lines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Diclofenac + prednisolone</b> </p> <p>59 per 100 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ketorolac + prednisolone</b> </p> <p>83 (60 to 100)</p> <p>per 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> </p> <p>(1.02 to 1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR &gt; 1 is better.</p> <p><a href="./references#CD004239-bbs2-0007" title="RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% versus ketorolac tromethamine 0.5% and prednisolone acetate 1%. Investigative Ophthalmology &amp; Visual Science2004;45:ARVO E‐abstract 2030. RhoDS , SollSM . Combination therapy for pseudophakic cystoid macular edema: diclofenac sodium 0.1% and prednisolone acetate 1% vs. ketorolac tromethamine 0.5% and prednisolone acetate 1%. American Academy of Ophthalmology2004:AAO-PO-201. ">Rho 2004</a> also reported this outcome in Snellen lines (MD 0.40, 95% CI −0.93 to 1.73; 68 participants)  </p> <p><a href="./references#CD004239-bbs2-0008" title="RhoDS , SollSM , MarkovitzBJ . Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoid macular edema. Investigative Ophthalmology &amp; Visual Science2006;47:ARVO E‐abstract 5211. ">Rho 2006</a> reported in ETDRS letters (MD 0.90, 95% CI −4.31 to 6.11; 34 participants) considering data from the diclofenac group or  </p> <p>(MD 1.20, 95% CI −4.58 to 6.98; 34 participants) considering </p> <p>data from the bromfenac group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of visual improvement one month after discontinuation of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in leakage on FFA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in central macular thickness on OCT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improved contrast sensitivity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not measured by any included trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and the associated 95% CI). </p> <p> </p> <p><b>CI:</b> confidence interval; <b>CME:</b> cystoid macular edema; <b>ETDRS:</b> Early Treatment Diabetic Retinopathy Study; <b>FFA:</b> fundus fluorescein angiography (angiogram); <b>NSAID:</b> non‐steroidal anti‐inflammatory drug; <b>OCT:</b> optical coherence tomography; <b>QoL:</b> quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for risk of bias (‐1), imprecision (‐1) and inconsistency (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NSAID versus active control in mixed cystoid macular edema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/full#CD004239-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004239-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NSAID versus placebo or active control in acute CME</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Proportion of participants with visual improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Ketorolac 0.5% vs vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Ketorolac 0.5% vs prednisolone 1.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3  Ketorolac 0.5% &amp; prednisolone 1.0% vs prednisolone 1.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Improvement in VA, Snellen lines* <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Ketorolac 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Ketorolac 0.5% &amp; Prednisolone 1.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Proportion of participants with improved FFA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Ketorolac 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Ketorolac 0.5% &amp; prednisolone 1.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Proportion of participants with improved contrast sensitivity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Ketorolac 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Ketorolac 0.5% &amp; prednisolone 1.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Proportion of participants with complete resolution* <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NSAID versus placebo or active control in acute CME</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004239-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">NSAID versus placebo in chronic CME</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Proportion of participants with visual improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Chronic CME, treatment ≤ 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.30, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Chronic CME, treatment 90‐120 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [1.58, 5.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Proportion of participants with visual improvement ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [1.17, 4.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Chronic CME, treatment ≤ 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.40, 4.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Chronic CME, treatment 90‐120 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [1.10, 8.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Proportion of participants with persistent visual improvement one month after discontinuation of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Topical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.51, 31.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.10, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Proportion of participants with improved FFA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.62, 6.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Proportion of participants with complete resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">NSAID versus placebo in chronic CME</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004239-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">NSAID versus active control in mixed CME</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Proportion of participants with visual improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Improvement in VA, Snellen lines* <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Improvement in VA, ETDRS letters* <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Diclofenac 0.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐4.31, 6.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Bromofenac 0.09%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐4.58, 6.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Proportion of participants with complete resolution* <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">NSAID versus active control in mixed CME</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004239.pub4/references#CD004239-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004239.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004239-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004239-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004239-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD004239-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD004239-note-0009">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD004239-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD004239-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004239-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004239\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004239\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004239\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004239\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004239\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004239.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004239.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004239.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004239.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004239.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725216308"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004239.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725216312"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004239.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e75d32daa1be5',t:'MTc0MDcyNTIxNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 